WO2015028104A1 - Novel drug combination - Google Patents
Novel drug combination Download PDFInfo
- Publication number
- WO2015028104A1 WO2015028104A1 PCT/EP2013/068528 EP2013068528W WO2015028104A1 WO 2015028104 A1 WO2015028104 A1 WO 2015028104A1 EP 2013068528 W EP2013068528 W EP 2013068528W WO 2015028104 A1 WO2015028104 A1 WO 2015028104A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibacterial agent
- use according
- fluorobenzamide
- fluoro
- hydroxyphenoxy
- Prior art date
Links
- 239000000890 drug combination Substances 0.000 title description 2
- QUHARGDBJJUOEB-UHFFFAOYSA-N 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide Chemical compound C1=C(F)C(CC)=CC(O)=C1OC1=CC=C(C(N)=O)C=C1F QUHARGDBJJUOEB-UHFFFAOYSA-N 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 45
- 208000015181 infectious disease Diseases 0.000 claims abstract description 44
- 229960004089 tigecycline Drugs 0.000 claims abstract description 33
- 229940126575 aminoglycoside Drugs 0.000 claims abstract description 28
- 229960005256 sulbactam Drugs 0.000 claims abstract description 26
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims abstract description 26
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 claims abstract description 22
- 229940041011 carbapenems Drugs 0.000 claims abstract description 21
- 230000000813 microbial effect Effects 0.000 claims abstract description 17
- 239000003242 anti bacterial agent Substances 0.000 claims description 147
- 229960002260 meropenem Drugs 0.000 claims description 104
- 229960004821 amikacin Drugs 0.000 claims description 101
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 100
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 98
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 68
- 108010078777 Colistin Proteins 0.000 claims description 57
- 229960003346 colistin Drugs 0.000 claims description 52
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 52
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 52
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 52
- 229960001225 rifampicin Drugs 0.000 claims description 26
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 17
- 229930182566 Gentamicin Natural products 0.000 claims description 17
- 229960002518 gentamicin Drugs 0.000 claims description 17
- 229960000707 tobramycin Drugs 0.000 claims description 17
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 17
- 241000589291 Acinetobacter Species 0.000 claims description 15
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 14
- 229960002182 imipenem Drugs 0.000 claims description 14
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 14
- 206010035664 Pneumonia Diseases 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 9
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical group C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229960004531 colistimethate sodium Drugs 0.000 claims description 6
- IQWHCHZFYPIVRV-VLLYEMIKSA-I colistin A sodium methanesulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].CC[C@@H](C)CCCCC(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC1=O IQWHCHZFYPIVRV-VLLYEMIKSA-I 0.000 claims description 6
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 6
- 238000011285 therapeutic regimen Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 4
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 claims description 4
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 229930193140 Neomycin Natural products 0.000 claims description 3
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 claims description 3
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010048038 Wound infection Diseases 0.000 claims description 3
- 229950006334 apramycin Drugs 0.000 claims description 3
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 claims description 3
- 229960005397 arbekacin Drugs 0.000 claims description 3
- MKKYBZZTJQGVCD-XTCKQBCOSA-N arbekacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)CC[C@H]1N MKKYBZZTJQGVCD-XTCKQBCOSA-N 0.000 claims description 3
- 229960003169 biapenem Drugs 0.000 claims description 3
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 claims description 3
- 208000037815 bloodstream infection Diseases 0.000 claims description 3
- 229960001127 colistin sulfate Drugs 0.000 claims description 3
- 229960000895 doripenem Drugs 0.000 claims description 3
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 3
- 229960002770 ertapenem Drugs 0.000 claims description 3
- 229960000318 kanamycin Drugs 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229930182823 kanamycin A Natural products 0.000 claims description 3
- 238000005399 mechanical ventilation Methods 0.000 claims description 3
- 229960004927 neomycin Drugs 0.000 claims description 3
- 229960000808 netilmicin Drugs 0.000 claims description 3
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims description 3
- 229950011346 panipenem Drugs 0.000 claims description 3
- 229960001914 paromomycin Drugs 0.000 claims description 3
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims description 3
- 229930184609 rhodostreptomycin Natural products 0.000 claims description 3
- 229960005322 streptomycin Drugs 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 31
- 150000001875 compounds Chemical class 0.000 description 192
- 230000001580 bacterial effect Effects 0.000 description 54
- 241000699670 Mus sp. Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 20
- 238000011081 inoculation Methods 0.000 description 20
- 230000004083 survival effect Effects 0.000 description 19
- 230000009467 reduction Effects 0.000 description 15
- 239000000725 suspension Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000002054 inoculum Substances 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 241000191967 Staphylococcus aureus Species 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000003993 interaction Effects 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- KFTLBUWBQDMTSQ-JNCWMXRTSA-N (4s,4as,5ar,12ar)-4-(dimethylamino)-n-[2-(dimethylamino)acetyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)NC(=O)CN(C)C)C(=O)[C@H]1N(C)C KFTLBUWBQDMTSQ-JNCWMXRTSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical group C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108020004256 Beta-lactamase Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000012809 post-inoculation Methods 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 4
- 238000003801 milling Methods 0.000 description 4
- 231100000417 nephrotoxicity Toxicity 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940124586 β-lactam antibiotics Drugs 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010021703 Indifference Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 3
- 229920003078 Povidone K 12 Polymers 0.000 description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000003096 antiparasitic agent Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229940124307 fluoroquinolone Drugs 0.000 description 3
- 229960003350 isoniazid Drugs 0.000 description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940048895 meronem Drugs 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000006070 nanosuspension Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960003500 triclosan Drugs 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 238000001238 wet grinding Methods 0.000 description 3
- 239000002132 β-lactam antibiotic Substances 0.000 description 3
- 208000035404 Autolysis Diseases 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 101150005343 INHA gene Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102220505380 Ubiquitin thioesterase ZRANB1_M26A_mutation Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940125687 antiparasitic agent Drugs 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 238000009640 blood culture Methods 0.000 description 2
- 238000002815 broth microdilution Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- MRGWUDKEBPXDJX-UHFFFAOYSA-N diazaborinine Chemical class B1=CC=CN=N1 MRGWUDKEBPXDJX-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- -1 hydroxyphenyl compound Chemical class 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- JPSLIQUWHBPNBM-NBKAJXASSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CS(O)(=O)=O.CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JPSLIQUWHBPNBM-NBKAJXASSA-N 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000028043 self proteolysis Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- KDTZBYPBMTXCSO-UHFFFAOYSA-N 2-phenoxyphenol Chemical group OC1=CC=CC=C1OC1=CC=CC=C1 KDTZBYPBMTXCSO-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000034950 Acinetobacter Infections Diseases 0.000 description 1
- 241000407321 Acinetobacter baumannii AYE Species 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 208000029329 Acinetobacter infectious disease Diseases 0.000 description 1
- 241001528221 Acinetobacter nosocomialis Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710198510 Enoyl-[acyl-carrier-protein] reductase [NADH] Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- 208000031998 Mycobacterium Infections Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- IABBAGAOMDWOCW-UHFFFAOYSA-N Nicametate citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)CCOC(=O)C1=CC=CN=C1 IABBAGAOMDWOCW-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-O butylazanium Chemical compound CCCC[NH3+] HQABUPZFAYXKJW-UHFFFAOYSA-O 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940023064 escherichia coli Drugs 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical class 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940045505 klebsiella pneumoniae Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000004841 phenylimidazoles Chemical class 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012808 pre-inoculation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YVOFSHPIJOYKSH-NLYBMVFSSA-M sodium rifomycin sv Chemical group [Na+].OC1=C(C(O)=C2C)C3=C([O-])C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O YVOFSHPIJOYKSH-NLYBMVFSSA-M 0.000 description 1
- KKVTYAVXTDIPAP-UHFFFAOYSA-M sodium;methanesulfonate Chemical compound [Na+].CS([O-])(=O)=O KKVTYAVXTDIPAP-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to methods of treating microbial infections, in particular infections caused by Acinetobacter baumannii, using novel combinations of known antibacterial agents.
- the present invention also relates to the use of such novel combinations as antibacterial medicaments and to pharmaceutical combinations containing such novel combinations.
- the bacterial fatty acid biosynthesis (FASII system) has generated substantial interest for the development of novel antibacterial and antiparasitic agents (Rock et al. J. Biol. Chem. 2006, 281 , 17541 ; Wright and Reynolds Curr. Opin. Microbiol. 2007, 10, 447).
- the organization of components in the bacterial fatty acid biosynthesis pathway based on discrete enzymes in some bacteria and parasites is fundamentally different from the multifunctional FASI system found in mammals, therefore allowing good prospects of selective inhibition.
- the overall high degree of conservation in many enzymes of the bacterial FASII system should also allow the development of broader-spectrum antibacterial and antiparasitic agents.
- FabI represents the enoyl-ACP reductase responsible of the last step of the fatty acid biosynthetic elongation cycle.
- FabI reduces the double bond in the trans-2- enoyl-ACP intermediate to the corresponding acyl-ACP product.
- This enzyme has been shown to constitute an essential target in major pathogens such as E. coli (Heath et al. J. Biol. Chem. 1995, 270, 26538; Bergler et al. Eur. J. Biochem. 1996, 242, 689) and S.
- isoniazid is a prodrug restricted to the treatment of susceptible tuberculosis.
- the fact that isoniazid requires activation by hydrogen-peroxide inducible enzymes enhances the possibilities of resistance by lack of activation or increased detoxification (Rosner et al. Antimicrob. Agents Chemother. 1993, 37, 2251 and ibid 1994, 38, 1829).
- triclosan a widely used consumer goods preservative with broad spectrum antimicrobial activity, has been found to be a reversible, tight-binding inhibitor of E. coli Fabl (Ward et al. Biochemistry 1999, 38, 12514).
- Derivatives based on the 2-hydroxydiphenyl ether core of triclosan have been reported (Tonge et al. J. Med. Chem.
- Acinetobacter baumannii (A. baumannii) is a pathogen which has extraordinary ability to acquire resistance to almost all groups of antibiotics and has the ability to survive for extended periods on environmental surfaces. Infection caused by A. baumannii has become a great concern in hospital settings due to high associated mortality rates, reported to be as high as 50% in some intensive care units (Montero et al. Antimicrobial Agents and Chemotherapy 2002, 1946-1952). Most A. baumannii strains isolated in hospitals today are highly resistant to modern noncarbapenem ⁇ -lactams, aminoglycosides and fluoroquinolones.
- Imipenem a carbapenem antibiotic used to be considered the "gold standard" therapy for severe infections, but many countries have reported growing resistance to carbapenems. Thus, there is a pressing need to develop new strategies for treatment that are effective against antibiotic resistant bacterial strains, in particular for the treatment of infection by A. baumannii.
- the compound of formula (I) (referred to herein as "compound (I)") is known chemically as 4-(4- ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide and has been found to be highly active in vitro against pathogenic methicillin-susceptible Staphylococcus aureus (MSSA), methicillin- resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains. Furthermore, compound (I) is also active in vivo in a murine model against MSSA, MRSA and VISA infections. Compound (I) has been evaluated in healthy human volunteers in a Phase I study and was reported to demonstrate ex vivo bactericidal activity against S. aureus.
- MSSA methicillin-susceptible Staphylococcus aureus
- MRSA methicillin- resistant Staphylococcus au
- the combination will have improved antibacterial characteristics compared with compound (I) and the known antibacterial agent, individually.
- the present inventors have discovered that combinations of 4-(4-ethyl-5-fluoro-2- hydroxyphenoxy)-3-fluorobenzamide (compound (I)) with certain known antibacterial agents (or classes of agents) exhibit improved anti-microbial activity, compared with 4-(4-ethyl-5-fluoro-2- hydroxyphenoxy)-3-fluorobenzamide alone, or the known antibacterial agent alone.
- the present invention provides a method of treating microbial infection comprising administering to a subject in need thereof a therapeutically effective amount of:
- an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
- the present invention provides 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use in treating microbial infection in a subject, in a therapeutic regimen comprising said 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide in combination with an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
- an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
- the present invention provides an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam for use in treating microbial infection in a subject, in a therapeutic regimen comprising said antibacterial agent in combination with 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide.
- the present invention provides the use of 4-(4-ethyl-5-fluoro-2- hydroxyphenoxy)-3-fluorobenzamide and an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam in the manufacture of a medicament for use in treating microbial infection.
- an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam in the manufacture of a medicament for use in treating microbial infection.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising 4-(4- ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide and an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
- novel combinations of compound (I) and an additional antibacterial agent can, both in vitro and in vivo, provide enhanced antibacterial activity against A. baumannii compared with compound (I) alone or the additional antibacterial agent alone.
- the present invention provides novel combination therapies which in at least some embodiments provide an improved method of treating microbial infection, in particular antibiotic-resistant microbial infection, such as antibiotic-resistant A. baumannii.
- Figure 1 shows minimum inhibitory concentration (MIC) distribution for compound (I) against 77 isolates of A. baumannii.
- Figure 2 shows MIC distribution for compound (I), amikacin, colistin, gentamicin, meropenem and tobramycin against 77 isolates of A. baumannii.
- Figure 3 shows a summary of checkerboard experiments with twenty A. baumannii isolates and combinations of compound (I) with amikacin, colistin, gentamicin, meropenem and tobramycin.
- Figures 4-9 show the bactericidal effects of compound (l)/amikacin combinations against various A. baumannii isolates.
- Figures 10-15 shows the bactericidal effects of compound (l)/meropenem combinations against various A. baumannii isolates.
- Figures 16-27 show the bactericidal effects of compound (l)/colistin combinations against various A. baumannii isolates.
- Figure 28 summarises the in vitro time kill kinetics of meropenem, amikacin and compound (I) alone or in combination, against A. baumannii SAN strain.
- Figure 29 shows the effect of antibacterial agent therapy on survival 72 hours post infection with A. baumannii for Study 1 of the mouse model (Example 6).
- Figure 30 shows the effect of antibacterial agent therapy on survival 48 hours post infection with A. baumannii for Study 3 of the mouse model (Example 6).
- the compound of formula (I) is 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide or a pharmaceutically acceptable salt or solvate thereof.
- salts are intended to indicate salts which are not harmful to the patient.
- Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts and pharmaceutically acceptable akaline addition salts.
- Acid addition salts include salts of inorganic acids as well as organic acids.
- suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
- suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p- aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like.
- compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference in its entirety.
- metal salts include lithium, sodium, potassium, magnesium salts and the like.
- ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
- alkaline salts include, for example, sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N- dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine, N-methylglucamine.
- bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N- dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benzylamine,
- solvates include hydrates. Additional antibacterial agents
- compound (I) is administered in combination with an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
- an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam is referred to herein as the "additional antibacterial agent”.
- Carbapenems are broad spectrum ⁇ -lactam antibacterial agents that exhibit antibacterial activity by interfering with bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs).
- PBPs are enzymes that catalyse the formation of peptidoglycan in the cell wall of bacteria. Bacterial cell wall formation is a dynamic process with formation and autolysis occurring and the same time. Therefore, when PBP function is inhibited, cell wall formation is interrupted while autolysis continues and the peptidoglycan weakens. Eventually the bacterial cell bursts due to osmotic pressure, leading to bacterial cell death.
- carbapenems include but are not limited to: meropenem, imipenem, ertapenem, doripenem, panipenem and biapenem.
- the carbapenem is meropenem or imipenem, suitably meropenem.
- Aminoglycosides are broad spectrum antibacterial agents that exhibit antibacterial activity by binding to the ribosomal decoding site, which has the effect of reducing the fidelity of protein synthesis.
- aminoglycosides include but are not limited to amikacin, gentamicin, tobramycin, arbekacin, kanamycin, neomycin, netilmicin, paromomycin, rhodostreptomycin, streptomycin and apramycin.
- the aminoglycoside antibacterial agent is amikacin, gentamicin or tobracmycin, suitably amikacin.
- polymixins A-E There are five different polymixin compounds, polymixins A-E, however only polymixins B and polymixin E are used in clinical practice.
- Polymixin E is also known as colistin, and is commercially available in cationic form as colistin sulfate, and in anionic form as colistin methanesulfonate sodium (colistimethate sodium (CMS)).
- the polymixin antibacterial agent is colistin, suitably colistin methanesulfonate sodium.
- Polymixin antibacterial agents target Gram-negative bacteria and exhibit antibacterial activity by binding to the lipopolysaccharide in the outer membrane of the bacteria, disrupting both the outer and inner membranes, leading to leakage of the intracellular contents and bacterial cell death.
- the most common adverse effect of colistin treatment is nephrotoxicity (renal toxicity) because the drug is excreted primarily by the kidneys and elevated blood levels may further impair renal function.
- Glycylcycline antibacterial agents are broad spectrum antibacterial agents that were developed as tetracycline analogues in order to overcome tetracycline resistance.
- This structural class of antibacterial agents is bacteriostatic, and act by binding to the bacterial 30S ribosomal subunit and by blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. Amino acid residues are prevented from becoming incorporated into elongating peptide chains, which leads to inhibition of protein synthesis.
- glycylcycline antibacterial agent presently available for clinical use is tigecycline, which is available only as an injectable formulation.
- the glycylcycline antibacterial agent is tigecycline. According to a review by Noskin, G.A. (Clinical Infectious Diseases 2005, S303-14) tigecycline has shown promise as a monotherapy and its use as part of a combination regimen has not been evaluated.
- Rifampicin is a bactericidal antibacterial agent of the rifamycin group and is typically used to treat Mycobacterium infections including tuberculosis and Hansen's disease. Rifampicin inhibits bacterial DNA-dependent RNA synthesis by inhibiting bacterial DNA-dependent RNA polymerase. The most serious adverse effect of administering rifampicin is hepatotoxicity.
- Sulbactam is a ⁇ -lactamase inhibitor which is typically administered in combination with a ⁇ -lactam antibiotic
- ⁇ -lactamases are enzymes which degrade ⁇ -lactam antibiotics, therefore when sulbactam binds to the enzyme it prevents degradation of the ⁇ -lactam antibiotic.
- the antibacterial agent in combination with compound (I) is selected from the group consisting of meropenem, imipenem, amikacin, gentamicin, tobramycin, colistin, tigecycline, rifampicin and sulbactam and is suitably selected from the group consisting of meropenem, amikacin and colistin.
- novel combinations of compound (I) with certain known antibacterial agents have potential utility for treating infection by microbial pathogens.
- the antibacterial combinations of the present invention can be used to treat microbial infection in humans and animals.
- Antibacterial combinations of the present invention are particularly useful in forming a therapeutic regimen having a selective spectrum of activity in vitro and in vivo against bacterial strains relying on Fabl and related targets.
- Such strains encompass Staphylococcus aureus including multiresistant strains (such as methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin- resistant Staphylococcus aureus (VRSA) strains), Acinetobacter strains (such as Acinetobacter baumannii), Bacillus anthracis, Chlamydophila pneumoniae, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Neisseria meningitidis and also bacteria such as Mycobacterium tuberculosis carrying homologous Fabl enzymes such as InhA or other organisms such as Plasmodium falciparum.
- MSSA methicillin-susceptible Staphylococcus aureus
- MRSA methicillin-resistant
- the antibacterial combination of the present invention is used in the treatment of human or animal microbial infection by Acinetobacter, in particular Acinetobacter baumannii.
- A. baumannii most frequent
- A. nosocomialis A. pitii
- A. calcoaceticus the fifth group has been only recently identified and has yet to be named (Nemec A., 2013, 9 th International Symposium on the Biology of Acinetobacter).
- A. baumannii accounts for about 80% of reported Acinetobacter infections
- A. baumannii is an emergent nosocomial pathogen which has also been isolated from soil and water samples in the environment, although infection rarely occurs outside of healthcare settings. Risk factors associated with A. baumannii include prolonged hospitalization, intensive care unit admission, invasive surgical procedures, previous treatment with antibiotics (such as imipenem and levofloxacin), chronic lung disease and alcoholism (Seifert H., 2013, 9 th International Symposium on the Biology of Acinetobacter).
- Acinetobacter causes a variety of diseases including blood stream infections, urinary tract infections, meningitis, wound infections especially in burns patients (Dijkshoorn L, 2013, 9 th International Symposium on the Biology of Acinetobacter), and pneumonia especially in patients on mechanical ventilation.
- Acinetobacter may also colonize in a patient without causing infections or symptoms, especially in tracheostomy sites or open wounds (http://www.cdc.gov/HAI/organisms/acinetobacter.html).
- Acinetobacter can be spread by person-to-person contact, airborne transmission, environmental surfaces and medical equipment (Seifert H., 2013, 9 th International Symposium on the Biology of Acinetobacter).
- the infection by A. baumannii is associated with a disease or disorder selected from the group consisting of a blood stream infection, a urinary tract infection, meningitis, a wound infection (especially in a burns patient) and pneumonia (especially in a patient on mechanical ventilation).
- Example 4 As shown in the checkerboard studies of Example 3, over 70% of the combinations of compound (I) and an additional antibacterial agent as defined herein exhibited additivity and/or synergy, with colistin in particular demonstrating synergy with compound (I). In Example 4, sub- MIC combinations of compound (I) and amikacin and meropenem were found to exhibit bactericidal activity (i.e. time to attain 99.9% bacterial killing, which is defined as a A3log10 reduction compared to initial inoculum).
- Example 6 In vivo studies (Example 6) using a mouse model of A. baumannii pneumonia demonstrated that administering combinations of compound (I) with amikacin and meropenem increased survival rates compared with administering amikacin and meropenem alone. A combination of compound (I) and colistin demonstrated greater efficacy than compound (I) alone.
- composition comprising:
- an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
- compound (I) and the additional antibacterial agent can be formulated as separate pharmaceutical compositions.
- kit of parts comprising:
- composition comprising an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
- an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
- kit of parts will typically be accompanied by instructions specifying the co-administration of (a) and (b).
- compositions can be formulated to be administered under oral, topical, parenteral including injectable routes, such as intravenous administration, with individual doses appropriate for the patient to be treated.
- compound (I) is not administered orally.
- compound (I) is formulated to be administered via parenteral routes.
- Compound (I) and the additional antibacterial agent will typically be formulated for administration via the same route, thus in one embodiment compound (I) and the additional antibacterial agent are both formulated for administration via parenteral routes.
- compound (I) and the additional antibacterial agent need not be formulated for administration via the same route.
- compound (I) may be formulated for administration via parenteral routes and the additional antibacterial agent formulated for oral administration.
- compositions according to the invention can be solid, liquid or in the form of a gel/cream and be present in the pharmaceutical forms commonly used in human medicine, such as for example, plain or sugar-coated tablets, gelatin capsules, granules, suppositories, injectable preparations, ointments, creams, gels; they are prepared according to the customary methods.
- the active ingredient/s can be incorporated using excipients which are customarily used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting agents, dispersants or emulsifiers, preservatives.
- excipients which are customarily used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting agents, dispersants or emulsifiers, preservatives.
- excipients which are customarily used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, aqueous or non-aqueous vehicles, fatty substances of animal or
- the pharmaceutical composition additionally comprises a solubilisation agent.
- the pharmaceutical composition additionally comprises an isotonic agent.
- the pharmaceutical composition additionally comprises a diluent.
- the diluent comprises water, such as QS water.
- compound (I) and the additional antibacterial agent are administered via the same route of administration.
- compound (I) and the additional antibacterial agent are both administered intravenously.
- compound (I) may be co-formulated with the additional antibacterial agent, or formulated separately.
- compound (I) is formulated separately from the additional antibacterial agent, but both compound (I) and the additional antibacterial agent are administered intravenously.
- compound (I) and the additional antibacterial agent are administered as a combination, i.e. they are co-administered.
- the co-administration may occur simultaneously or sequentially.
- compound (I) and the additional antibacterial agent are administered simultaneously. Simultaneous administration can involve the co-formulation of compound (I) and the additional antibacterial agent. Alternatively, compound (I) and the additional antibacterial agent can be formulated separately, but administered to the patient at the same time. Suitably, compound (I) and the additional antibacterial agent will be administered simultaneously, via separate or the same parenteral routes. In one embodiment, compound (I) and the additional antibacterial agent are administered sequentially. In one embodiment, compound (I) is administered prior to the additional antibacterial agent. In another embodiment, the additional antibacterial agent is administered prior to compound (I). In a therapeutic regimen comprising sequential administration either:
- compound (I) is administered to a subject, then after a period of time the additional antibacterial agent is administered to the subject; or
- the additional antibacterial agent is administered to a subject, then after a period of time compound (I) is administered to the subject.
- the period of time between administration of the two agents may be up to 12 hours, for example up to 1 1 hours, up to 10 hours, up to 9 hours, up to 8 hours, up to 7 hours, up to 6 hours, up to 5 hours, up to 4 hours, up to 3 hours, up to 2 hours, up to 1 hour, up to 50 minutes, up to 45 minutes, up to 30 minutes, up to 25 minutes, up to 20 minutes, up to 15 minutes, up to 10 minutes, up to 9 minutes, up to 8 minutes, up to 7 minutes, up to 6 minutes, up to 5 minutes, up to 4 minutes, up to 3 minutes, up to 2 minutes, up to 1 minutes or up to 30 seconds.
- the combination of compound (I) and the additional antibacterial agent may be administered as a daily dosage, or may be administered at more frequent intervals such as twice daily. Treatment should be continued for as long as required to receive the benefit of the invention.
- the dosage of compound (I) in the combination will be lower than the MIC of compound (I) when administered as a monotherapy.
- the dosage of the additional antibacterial agent in the combination will be lower than the MIC of the additional antibacterial agent when administered as a monotherapy.
- the individual dosages of compound (I) and the additional antibacterial agent in the combination will both be lower than their respective MICs when administered as a monotherapy.
- the dosage of compound (I) in the combination will be between about 1000 mg/kg and about 0.1 mg/kg, such as between about 800 mg/kg and about 1 mg/kg, between about 500 mg/kg and about 10 mg/kg or between about 300 mg/kg and about 100 mg/kg, such as about 200 mg/kg.
- an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 50 mg/kg of a carbapenem, dosed simultaneously or sequentially.
- the dosage of aminoglycoside will be between about 1000 mg/kg and about 0.1 mg/kg, such as between about 800 mg/kg and about 1 mg/kg, between about 500 mg/kg and about 5 mg/kg or between about 50 mg/kg and about 5 mg/kg, such as about 18 mg/kg.
- an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 18 mg/kg of an aminoglycoside, dosed simultaneously or sequentially.
- the additional antibacterial agent is a polymixin such as colistimethate sodium
- typically the dosage of polymixin will be between about 1000 mg/kg and about 0.1 mg/kg, such as between about 800 mg/kg and about 0.1 mg/kg, between about 500 mg/kg and about 0.5 mg/kg, between about 50 mg/kg and about 0.5 mg/kg, or between about 10 mg/kg and about 1 mg/kg, such as about 5 mg/kg.
- an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 5 mg/kg of polymixin, dosed simultaneously or sequentially.
- the additional antibacterial agent is a glycylcycline such as tigecycline
- the dosage of glycylcycline will be between about 1000 mg/kg and about 0.1 mg/kg, such as between about 800 mg/kg and about 0.1 mg/kg, between about 500 mg/kg and about 0.1 mg/kg, or between about 300 mg/kg and about 0.1 mg/kg, such as about 1 -2 mg/kg.
- an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 2 mg/kg of glycylcycline, dosed simultaneously or sequentially.
- the dosage of rifampicin will be between about 1000 mg/kg and 0.1 mg/kg, such as between about 800 mg/kg and 1 mg/kg, or between about 600 mg/kg and about 1 mg/kg, such as about 20 mg/kg.
- an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 20 mg/kg of rifampicin, dosed simultaneously or sequentially.
- the dosage of sulbactam will be between about 300 mg/kg and about 1 mg/kg, such as between about 150 mg/kg and about 1 mg/kg, or between about 100 mg/kg and about 10 mg/kg, such as about 50 mg/kg.
- an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 50 mg/kg of sulbactam, dosed simultaneously or sequentially.
- Minimum inhibitory concentration as used herein refers to the lowest concentration of an antibacterial agent that will inhibit the visible growth of a bacterial strain after overnight incubation.
- aminoglycoside-resistant isolates e.g. "AMK-R”
- Compound (I) was prepared in-house according to the method described in Example 1 . Amikacin, tobramycin, meropenem, colistin and gentamicin were all obtained from Sigma.
- MIC endpoints were determined by broth microdilution according to CLSI guidelines (CLSI, M7-A8 & M100-S22, 2012). Panels were prepared at IHMA using cation-adjusted Mueller-Hinton broth. Colonies were taken directly from a second- pass culture plate and prepared to a suspension equivalent of the 0.5 McFarland standard using normal saline. Inoculation of the MIC plates took place within 15 minutes after adjustment of the inoculum suspension turbidity. The panels were incubated at 35 °C for 20-24 hours before reading the MIC endpoints.
- Compound (I) may be prepared using the procedures outlined in international application WO 201 1/026529.
- the procedure corresponding to "Example 1 (Alternative Procedure)" of WO 201 1/026529 is outlined below:
- MIC minimum inhibitory concentration
- Compound (I) exhibited good activity against the majority of the 77 isolates tested in this study with MICs ranging from 0.5-8, 2-8, 0.25->32 and 2->32 ⁇ g/ml against susceptible, amikacin-R, colistin-R and meropenem-R isolates respectively. Although the overall MIC range was quite broad, the majority of Compound (I) MICs were in the range of 2-8 ⁇ g/ml. The mode MIC was 4 ⁇ g/ml ( Figure 1 ).
- MPM-R-1 8 4 >24h >24h 1.4h* 1.2h 3.8h* 2.1 h* 1.5h 1.2h
- MPM-R-2 4 8 >24h >24h 1.3h 1.2h 4.7h* 1.8h* 1.4h 1.2h
- MPM-R-3 4 4 >24h >24h 1.4h* 1.2h 2.6h* 1.8h 1.4h 1.2h
- Phenotype (1) MPM I xMIC 4xMIC I xMIC 4xMIC 1 x/1 x 4x/4x
- AMK-R-1 4 4 >24h >24h 5.2h* 3.2 6.5h* 4.3h 3.2h 2.7h
- AMK-R-3 2 16 >24h >24h 3.6h 1.8h 6.3h 3.9h 3.7h 3.5h
- COL-R-2 4 0.25 >24h >24h >24h 5.8h* >24h >24h 12.8h 6.8h I COL-R-3 I 16 I 6 I >24h >24h
- A.baumannii isolates (phenotypes) are illustrated in Figures 16-27 and summarised in Table 8.
- Phenotype (1) COL 1 xMIC 4xMIC 1 xMIC 4xMIC 1 x/1 x 4x/4x
- MPIV1-R-1 8 0.25 >24h >24h 5.0h* 8.1 h >24h >24h 15.1 h 14.7h
- MPM-R-1 4 1 >24h >24h 1.3h* 1.6h* >24h >24h 9.6h 4.7h
- AMK-R-1 4 0.5 >24h >24h 1.4h* 1.3h* >24h >24h 23.5h 2.8h
- AMK-R-2 4 0.5 >24h >24h 2.3h* 1.8h >24h >24h >24h 4.3h
- AMK-R-3 2 0.25 >24h >24h >24h 2.9h* >24h >24h >24h >24h
- COL-R-1 8 8 >24h >24h 2.8h* 2.3h >24h >24h 1 1.4h 5.0h
- the additional antibacterial agents amikacin, meropenem and colistin, were generally bactericidal ( ⁇ 99.9% bacterial killing) against the majority of isolates when tested at 4x MIC and against many isolates when tested at 1 x MIC.
- compound (I) 4x/additional antibacterial agent 4x MIC combinations resulted in the same effects as when the comparator was tested alone. This also held true for compound (I) 1 x/additional antibacterial agent 1 x MIC combinations though not for all isolates tested.
- Compound (I) was supplied by NOVASEP-FINORGA. Methanol was added to 5 mg of compound (I) in order to obtain a 20 mg/mL solution.
- Amikacin was supplied by MYLAN LAB. A solution containing 50 mg/mL of amikacin was diluted in saline solution and used immediately after dilution in order to obtain a concentration of 1.8 mg/mL.
- Meropenem was supplied by ASTRA ZENECA as Meronem®. A solution containing 50 mg/mL of meropenem was diluted in saline solution and used immediately after dilution in order to obtain a concentration of 5 mg/mL.
- Colistin was supplied by SANOFI-AVENTIS as Colimycine®. 3 mL of saline solution was added onto 33.33 mg of colistin powder in order to obtain a 1 1.1 1 mg/mL solution.
- A. baumanni isolates A. baumannii CIP 5377 (ATCC® 17978): low cephalosporinase producing strain, susceptible to meropenem and amikacin, isolated in an infected patient
- A. baumannii CIP 7034 low cephalosporinase producing strain, susceptible to meropenem and amikacin
- A. baumannii AYE ATCC® BAA1710TM extended spectrum beta-lactamase producing strain susceptible to meropenem and resistant to amikacin
- A. baumannii SAN-94040 cephalosporinase-overproducing strain, susceptible to meropenem and intermediate to amikacin and resistant to fluoroquinolones, isolated from blood cultures of an intensive care patient with nosocomial pneumonia from North Africa (Algeria).
- A. baumannii RCH-69 cephalosporinase producing strain; low susceptibility to imipenem and resistant to amikacin.
- MIC Minimum inhibitory concentration
- Compound (I) exhibited good activity against the 5 isolates of A. baumannii tested in this study with MICs ranging from 1 to 2 ⁇ g mL against susceptible, amikacin-R and meropenem-R isolates.
- Time-kill kinetics were performed at 37°C by testing compound (I) and selected antimicrobial agents individually at 2x the corresponding MIC of each antibacterial agent.
- a second set of experiments involved the testing of compound(l)/additional antibacterial agent combinations of 2x/2x MIC. Samples were taken at 0, 3, 6 and 24 hours in order to determine colony forming units (CFU/mL). Bactericidal activity was defined by a reduction of the inoculum by 3 Iog10 compared to initial inoculum (10 5 CFU/mL) at a defined time point (CLSI M26A, 1999).
- compound (I) was observed to be bacteriostatic when tested alone at 2x MIC.
- the additional antibacterial agents amikacin and meropenem were observed to be bactericidal when tested alone at 2x MIC.
- the aim of this study was to investigate the efficacy of co-administration of compound (I) with amikacin, meropenem or colistin, in a mouse model of A. baumannii pneumonia infected via the intra-tracheal route.
- Compound (I) was supplied as a nanosuspension, prepared by wet milling as follows.
- the milling medium was prepared by dissolving a polymer, PVP (polyvinylpyrrolidone)! 2PF (Kollidon 12 PF, BASF), at 50.0 mg/mL in purified water at 50 mL scale. The solution was added to a 250 mL clear glass vial (Type II), followed by addition of compound (I) at 100 mg/mL. To avoid aggregation, immediately after compounding a pre-suspension was made by stirring using a magnetic stirrer for 30 minutes. Finally, the milling beads were added. 225 g of ytrium stabilized zirconium oxide beads with a diameter of 0.5 mm were added.
- the vial was closed and placed on a roller mill (Peira, Beerse, Belgium) for the wet milling process.
- the vial speed was set at 160 rpm (setting 600).
- a sample was taken for analysis of particle size distribution using laser diffraction, type Mastersizer 2000 (Malvern, Worcestershire, UK) to confirm that at least 90% of the suspended particles were inferior to 500 nm in diameter and the milling process was stopped.
- the white homogeneous nanosuspension was then harvested from the milling beads using a syringe with a 23G needle.
- SAN-94040 cephalosporinase-overproducing strain, susceptible to meropenem and intermediate to amikacin and resistant to fluoroquinolones, isolated from blood cultures of an intensive care patient with nosocomial pneumonia from North Africa (Algeria).
- the SAN strain is responsible for an average of 80% mortality rate in this mice pneumonia model.
- RCH-69 cephalosporinase producing strain; low susceptibility to imipenem and resistant to amikacin.
- the bacterial inoculum was prepared in order to obtain a suspension containing 10 8 CFU/mL of Acinetobacter baumannii in saline.
- mice were individually marked and housed in cages containing five animals/cage under ventilated and controlled (temperature and humidity) atmosphere.
- the mice were rendered transiently neutropenic by 2 intra-peritoneal (IP) injections of 150 ⁇ _ of cyclophosphamide (Endoxan® 150 mg/kg) 4 (D-4) and 3 (D-3) days before the Acinetobacter baumannii inoculation (Day 0).
- IP intra-peritoneal
- End-4 cyclophosphamide
- D-3 3 days before the Acinetobacter baumannii inoculation (Day 0).
- This transient immunosuppression was sufficient to facilitate the development of the A. baumannii pneumonia while allowing the recovery of the neutrophil influx 2 (Day 2) days after inoculation in order to avoid or limit a systemic bacterial dissemination.
- mice were anesthetized by a mixture of oxygen and isoflurane.
- the bacterial inoculation was performed on Day 0 by intra-tracheal installation using an endotracheal catheter (50 ⁇ of the suspension, thus 5.106 CFU).
- the positioning of the catheter in the trachea was checked by a "ring test”.
- the bacterial count in lungs was checked for all study groups by sacrificing one mouse immediately after inoculation.
- the survival rates were compared with the Chi-square test or the Fisher exact test as appropriate.
- the survival curves were compared by the Kaplan-Meier method.
- Tissue samples preparation At each time point, three mice were sacrificed per group. Lungs, kidneys, liver and spleen were collected after the blood sampling and cervical dislocation. Tissues were wiped with a sterile gauze to remove blood contaminant outside. Tissues were then be weighed, finely ground and plated on agar for quantitative culture. Cultures were incubated at 37°C for 18 to 24 hours.
- the survival rates were be compared with the Chi-square test or the Fisher exact test as appropriate.
- the survival curves were compared by the Kaplan-Meier method.
- mice were administered, 3 hours post-inoculation of A. baumannii SAN-94040 via intratracheal route, with compound (I) via intra-peritoneal route at 200 mg/kg 3 times daily (every 8 hours) for 1 day alone and in combination with meropenem at 50 mg/kg 3 times daily (every 8 hours) for 1 day or with amikacin at 18 mg/kg 3 times daily (every 8 hours) for 1 day.
- mice were allocated into 6 groups as shown in Table 10.
- the SAN-94040 strain of A. baumannii is susceptible to meropenem and has intermediate susceptibility to amikacin.
- mice were administered with 200 ⁇ of a 20 mg/mL compound (I) suspension obtained by diluting 2.183 mL of the 45.8 mg/mL suspension in 2.817 mL of 0.9% NaCI aqueous solution.
- mice were administered with 100 ⁇ of a 40 mg/mL compound (I) suspension obtained by diluting 4.367 mL of the 45.8 mg/mL suspension in 0.683 mL of 0.9% NaCI aqueous solution.
- Meropenem was supplied by ASTRA ZENECA (Meronem®) (50 mg of meropenem/mL). Diluted solution was used extemporaneously after dilution in 0.9 % NaCI. Amikacin was supplied by MYLAN LAB (Amiklin®) (50 mg of amikacin/mL). Diluted solution was used extemporaneously after dilution in 0.9 % NaCI.
- the SAN-94040 strain of A. baumannii has intermediate susceptibility to amikacin, and since amikacin does not penetrate very well into the lungs, it was not unexpected that all animals died within 72 hours post-infection when treated with amikacin alone or with amikacin + compound (I).
- mice were administered, 3 hours post-inoculation of A. baumannii SAN-94040 via intra-tracheal route, with compound (I) via intra-peritoneal route at 200 mg/kg 3 times daily (every 8 hours) for 1 day alone and in combination with meropenem at 50 mg/kg 3 times daily (every 8 hours) for 1 day or with amikacin at 18 mg/kg 3 times daily (every 8 hours) for 1 day.
- 90 mice were allocated into 6 groups shown in Table 12.
- the SAN-94040 strain of A. baumannii is susceptible to meropenem and has intermediate susceptibility to amikacin.
- Table 12 Study 2 design
- mice were allocated into 6 groups as follow:
- mice were administered with 100 ⁇ of the 46.5 mg/mL compound (I) suspension.
- Amikacin supplied by MYLAN LAB (Amiklin®) (50 mg of amikacin/mL). Diluted solution was used extemporaneously after dilution in 0.9 % NaCI.
- Table 13 Results of lung bacterial counts of A. baumannii CFU / g Lung TO 24h sd* 48 h sd* 72h sd* control 3.33E+06 1.81 E+10 1.58E+W 1.82E + 10 7.91E+09 2.50E+02 i.ooE + oo compound (1) 4.72E +09 4.99E+09 3.75E+05 1.00E+00
- control mice had positive lung cultures, reflecting the virulence of the infection model.
- administration of a combination of compound (I) with meropenem reduced bacterial counts in lungs compared to control, and the reduction was greater than with administration of compound (I) or meropenem alone.
- administration of a combination of compound (I) with amikacin reduced bacterial counts in lungs compared to control, and the reduction was greater than with administration of compound (I) or amikacin alone.
- Table 15 Results of spleen bacterial counts of A baumannii CFU / g Spleen TO 24h sd* 48h sd* 72h sd*
- Table 17 Results of kidney bacterial counts of Acinetobacter baumannii compound (1) - 2.36 10 8 10 s 2.4 10 5 o - amikacin - 1 .09 10 7 1.8 io 7 6.8 10 5 9.710 s - meropenem - 1 .34 10 4 toe io 4 0 o 0 o compound (1) +
- mice were allocated into 6 groups as follows.
- the RCH-69 strain of A. baumannii has low susceptibility to imipenem, is assumed to have a low susceptibility to meropenem and is resistant to amikacin.
- mice were allocated into 6 groups as follow:
- mice were administered with 100 ⁇ of the 47.1 mg/mL compound (I) suspension.
- mice of the control group died within 48 hours following the inoculation of Acinetobacter baumannii RCH-69 (intermediate to imipenem and susceptible to colistin) as expected in this model of acute pneumonia.
- the mice administered with compound (I) at 200 mg/kg Q8h for 3 days died within 48 hours post-infection and the mice administered with meropenem at 50 mg/kg Q8h for 3 days died also within 48 hours post-infection as expected as RCH-69 strain has a low susceptibility to carbapenems.
- Treatments using a combination of compound (I) and meropenem or a combination of meropenem and colistin exhibited significant efficacy compared to the control group or compound (I) alone or meropenem alone.
- a combination of compound (I) and meropenem demonstrated increased survival rate (40%) compared to a combination of meropenem and colistin (20%) at 48 hours post-infection (Figure 30).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
There isprovidedinter aliaa method of treating microbial infection comprising administering to a subject in need thereof a therapeutically effective amount of: (a) 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide; and (b) an antibacterial agentselected from the group consisting of carbapenems, aminoglycosides, polymixins,glycylcyclines,rifampifinand sulbactam.
Description
NOVEL DRUG COMBINATION
Field of the invention
The present invention relates to methods of treating microbial infections, in particular infections caused by Acinetobacter baumannii, using novel combinations of known antibacterial agents. The present invention also relates to the use of such novel combinations as antibacterial medicaments and to pharmaceutical combinations containing such novel combinations.
Background of the invention
The emergence of antibiotic-resistant pathogens has become a serious worldwide healthcare problem. Indeed, some infections are now caused by multi-drug resistant organisms that are no longer responsive to currently available treatments. There is therefore an immediate need for new antibacterial agents and formulations with a novel mode of action.
The bacterial fatty acid biosynthesis (FASII system) has generated substantial interest for the development of novel antibacterial and antiparasitic agents (Rock et al. J. Biol. Chem. 2006, 281 , 17541 ; Wright and Reynolds Curr. Opin. Microbiol. 2007, 10, 447). The organization of components in the bacterial fatty acid biosynthesis pathway based on discrete enzymes in some bacteria and parasites is fundamentally different from the multifunctional FASI system found in mammals, therefore allowing good prospects of selective inhibition. The overall high degree of conservation in many enzymes of the bacterial FASII system should also allow the development of broader-spectrum antibacterial and antiparasitic agents.
Among all the monofunctional enzymes of the bacterial FASII system, FabI represents the enoyl-ACP reductase responsible of the last step of the fatty acid biosynthetic elongation cycle. Using the cofactor NAD(P)H as a hydride source, FabI reduces the double bond in the trans-2- enoyl-ACP intermediate to the corresponding acyl-ACP product. This enzyme has been shown to constitute an essential target in major pathogens such as E. coli (Heath et al. J. Biol. Chem. 1995, 270, 26538; Bergler et al. Eur. J. Biochem. 1996, 242, 689) and S. aureus (Heath et al. J. Biol. Chem. 2000, 275, 4654). However, other isoforms have been isolated such as FabK from S. pneumoniae (Heath et al. Nature 2000, 406, 145) and FabL from B. subtilis (Heath et al. J. Biol. Chem. 2000, 275, 40128). Although FabK is structurally and mechanistically unrelated to FabI (Marrakchi et al. Biochem J. 2003, 370, 1055), the similarity of FabI with FabL (β. subtilis), InhA (M. tuberculosis) and PfENR (P. falciparum) still offers opportunities of interesting activity spectra (Heath et al. Prog. Lipid Res. 2001 , 40, 467).
Several FabI inhibitors have already been reported in the literature (Tonge et al. Acc. Chem. Res. 2008, 41 , 1 1 ). Some of them such as diazaborines (Baldock et al. Science 1996, 274, 2107) and isoniazid in its activated form (Tonge et al. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13881 ) act by covalently modifying the cofactor NAD+. However some drawbacks are associated with these products. Diazaborines are only used experimentally because of their inherent toxicity (Baldock et al. Biochem. Pharmacol. 1998, 55, 1541 ) while isoniazid is a prodrug restricted to the treatment of susceptible tuberculosis. The fact that isoniazid requires
activation by hydrogen-peroxide inducible enzymes (Schultz et al. J. Am. Chem. Soc. 1995, 1 17, 5009) enhances the possibilities of resistance by lack of activation or increased detoxification (Rosner et al. Antimicrob. Agents Chemother. 1993, 37, 2251 and ibid 1994, 38, 1829).
Other inhibitors act by interacting noncovalently with the enzyme-cofactor complex. For instance triclosan, a widely used consumer goods preservative with broad spectrum antimicrobial activity, has been found to be a reversible, tight-binding inhibitor of E. coli Fabl (Ward et al. Biochemistry 1999, 38, 12514). Intravenous toxicology studies on this compound indicated a LD50 on rats of 29 mg/kg clearly ruling out intravenous injection (Lyman et al. Ind. Med. Surg. 1969, 38, 42). Derivatives based on the 2-hydroxydiphenyl ether core of triclosan have been reported (Tonge et al. J. Med. Chem. 2004, 47, 509, ACS Chem Biol. 2006, 1 , 43 and Bioorg. Med. Chem. Lett. 2008, 18, 3029; Surolia et al. Bioorg. Med. Chem. 2006, 14, 8086 and ibid 2008, 16, 5536; Freundlich et al. J. Biol. Chem. 2007, 282, 25436) as well as other inhibitors based on various classes of high throughput screening derived templates (Seefeld et al. Bioorg. Med. Chem. Lett. 2001 , 1 1 , 2241 and J. Med. Chem. 2003, 46, 1627; Heerding et al. Bioorg. Med. Chem. Lett. 2001 , 1 1 , 2061 ; Miller et al. J. Med. Chem. 2002, 45, 3246; Payne et al. Antimicrob. Agents Chemother. 2002, 46, 31 18; Sacchettini et al. J. Biol. Chem. 2003, 278, 20851 ; Moir et al. Antimicrob. Agents Chemother. 2004, 48, 1541 ; Montellano et al. J. Med. Chem. 2006, 49, 6308; Kwak et al. Int. J. Antimicro. Ag. 2007, 30, 446; Lee et al. Antimicrob. Agents Chemother. 2007, 51 , 2591 ; Kitagawa et al. J. Med. Chem. 2007, 50, 4710, Bioorg. Med. Chem. 2007, 15, 1 106 and Bioorg. Med. Chem. Lett. 2007, 17, 4982; Takahata et al. J. Antibiot. 2007, 60, 123; Kozikowski et al. Bioorg. Med. Chem. Lett. 2008, 18, 3565), nevertheless none of these inhibitors has succeeded yet as a drug. Interestingly, some classes of these inhibitors display activity on both Fabl and FabK: predominantly FabK for the dual compounds based on phenylimidazole derivatives of 4-pyridones (Kitagawa et al. J. Med. Chem. 2007, 50, 4710), predominantly Fabl for the indole derivatives (Payne et al. Antimicrob. Agents Chemother. 2002, 46, 31 18; Seefeld et al. J. Med. Chem. 2003, 46, 1627). However, the moderate activity on the second enzyme might prove to be a drawback for such compounds as it may lead to an increase of resistance mechanisms due to the added selection pressure (Tonge et al. Acc. Chem. Res. 2008, 41 , 1 1 ).
Despite the attractiveness of Fabl as an antibacterial/antiparasitic target, however, it is still largely unexploited at this time.
Acinetobacter baumannii (A. baumannii) is a pathogen which has extraordinary ability to acquire resistance to almost all groups of antibiotics and has the ability to survive for extended periods on environmental surfaces. Infection caused by A. baumannii has become a great concern in hospital settings due to high associated mortality rates, reported to be as high as 50% in some intensive care units (Montero et al. Antimicrobial Agents and Chemotherapy 2002, 1946-1952). Most A. baumannii strains isolated in hospitals today are highly resistant to modern noncarbapenem β-lactams, aminoglycosides and fluoroquinolones. Imipenem (a carbapenem antibiotic) used to be considered the "gold standard" therapy for severe infections, but many countries have reported growing resistance to carbapenems.
Thus, there is a pressing need to develop new strategies for treatment that are effective against antibiotic resistant bacterial strains, in particular for the treatment of infection by A. baumannii.
International application WO 2007/135562 (Mutabilis SA) describes a series of hydroxyphenyl derivatives that display a selective spectrum of activity on species containing Fabl and related targets, in contrast to Triclosan. A specific hydroxyphenyl compound of formula (I) is described in international application WO 201 1/026529 (FAB Pharma SAS):
The compound of formula (I) (referred to herein as "compound (I)") is known chemically as 4-(4- ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide and has been found to be highly active in vitro against pathogenic methicillin-susceptible Staphylococcus aureus (MSSA), methicillin- resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains. Furthermore, compound (I) is also active in vivo in a murine model against MSSA, MRSA and VISA infections. Compound (I) has been evaluated in healthy human volunteers in a Phase I study and was reported to demonstrate ex vivo bactericidal activity against S. aureus.
It is an object of the present invention to provide a novel combination therapy comprising compound (I) and another known antibacterial agent. Suitably, the combination will have improved antibacterial characteristics compared with compound (I) and the known antibacterial agent, individually. In particular, it is an object of the present invention to provide an effective combination regimen for treating infection caused by Acinetobacter baumannii.
Summary of the invention
The present inventors have discovered that combinations of 4-(4-ethyl-5-fluoro-2- hydroxyphenoxy)-3-fluorobenzamide (compound (I)) with certain known antibacterial agents (or classes of agents) exhibit improved anti-microbial activity, compared with 4-(4-ethyl-5-fluoro-2- hydroxyphenoxy)-3-fluorobenzamide alone, or the known antibacterial agent alone.
Thus, in a first aspect, the present invention provides a method of treating microbial infection comprising administering to a subject in need thereof a therapeutically effective amount of:
(a) 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide; and
(b) an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
In second aspect, the present invention provides 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use in treating microbial infection in a subject, in a therapeutic regimen comprising said 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide in combination with
an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
In a third aspect, the present invention provides an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam for use in treating microbial infection in a subject, in a therapeutic regimen comprising said antibacterial agent in combination with 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide.
In a fourth aspect, the present invention provides the use of 4-(4-ethyl-5-fluoro-2- hydroxyphenoxy)-3-fluorobenzamide and an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam in the manufacture of a medicament for use in treating microbial infection.
In a fifth aspect, the present invention provides a pharmaceutical composition comprising 4-(4- ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide and an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
As shown in the Examples, novel combinations of compound (I) and an additional antibacterial agent can, both in vitro and in vivo, provide enhanced antibacterial activity against A. baumannii compared with compound (I) alone or the additional antibacterial agent alone. Thus, the present invention provides novel combination therapies which in at least some embodiments provide an improved method of treating microbial infection, in particular antibiotic-resistant microbial infection, such as antibiotic-resistant A. baumannii.
Brief description of the figures
Figure 1 shows minimum inhibitory concentration (MIC) distribution for compound (I) against 77 isolates of A. baumannii.
Figure 2 shows MIC distribution for compound (I), amikacin, colistin, gentamicin, meropenem and tobramycin against 77 isolates of A. baumannii.
Figure 3 shows a summary of checkerboard experiments with twenty A. baumannii isolates and combinations of compound (I) with amikacin, colistin, gentamicin, meropenem and tobramycin. Figures 4-9 show the bactericidal effects of compound (l)/amikacin combinations against various A. baumannii isolates.
Figures 10-15 shows the bactericidal effects of compound (l)/meropenem combinations against various A. baumannii isolates.
Figures 16-27 show the bactericidal effects of compound (l)/colistin combinations against various A. baumannii isolates.
Figure 28 summarises the in vitro time kill kinetics of meropenem, amikacin and compound (I) alone or in combination, against A. baumannii SAN strain.
Figure 29 shows the effect of antibacterial agent therapy on survival 72 hours post infection with A. baumannii for Study 1 of the mouse model (Example 6).
Figure 30 shows the effect of antibacterial agent therapy on survival 48 hours post infection with A. baumannii for Study 3 of the mouse model (Example 6).
Detailed description of the invention
4-(4-Ethyl-5-fluoro-2-hvdroxyphenoxy)-3-fluorobenzamide (compound (I))
General processes for synthesising the compound of formula (I) are disclosed in WO 2007/135562, the contents of which is incorporated by reference in its entirety. A specific method for synthesising the compound of formula (I) is set out in Example 1 of the present application, and corresponds to the procedure provided in "Example 1 (Alternative procedure)" of WO 201 1/026529, the contents of which is also incorporated by reference in its entirety.
The compound of formula (I) is 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide or a pharmaceutically acceptable salt or solvate thereof.
In the present context, the term "pharmaceutically acceptable salt" is intended to indicate salts which are not harmful to the patient. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts and pharmaceutically acceptable akaline addition salts. Acid addition salts include salts of inorganic acids as well as organic acids.
Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p- aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference in its entirety. Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
Representative examples of alkaline salts include, for example, sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, ethylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N- dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, piperidine, piperazine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine, N-methylglucamine.
Examples of solvates include hydrates.
Additional antibacterial agents
In the methods and uses of the invention, compound (I) is administered in combination with an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam. The antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam is referred to herein as the "additional antibacterial agent".
Carbapenems
Carbapenems are broad spectrum β-lactam antibacterial agents that exhibit antibacterial activity by interfering with bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). PBPs are enzymes that catalyse the formation of peptidoglycan in the cell wall of bacteria. Bacterial cell wall formation is a dynamic process with formation and autolysis occurring and the same time. Therefore, when PBP function is inhibited, cell wall formation is interrupted while autolysis continues and the peptidoglycan weakens. Eventually the bacterial cell bursts due to osmotic pressure, leading to bacterial cell death.
Examples of carbapenems include but are not limited to: meropenem, imipenem, ertapenem, doripenem, panipenem and biapenem. In one embodiment, the carbapenem is meropenem or imipenem, suitably meropenem.
Aminoglycosides
Aminoglycosides are broad spectrum antibacterial agents that exhibit antibacterial activity by binding to the ribosomal decoding site, which has the effect of reducing the fidelity of protein synthesis.
Examples of aminoglycosides include but are not limited to amikacin, gentamicin, tobramycin, arbekacin, kanamycin, neomycin, netilmicin, paromomycin, rhodostreptomycin, streptomycin and apramycin. In one embodiment, the aminoglycoside antibacterial agent is amikacin, gentamicin or tobracmycin, suitably amikacin.
Treatment with aminoglycosides can cause side effects including ototoxicity and nephrotoxicity. Polymixins
There are five different polymixin compounds, polymixins A-E, however only polymixins B and polymixin E are used in clinical practice. Polymixin E is also known as colistin, and is commercially available in cationic form as colistin sulfate, and in anionic form as colistin methanesulfonate sodium (colistimethate sodium (CMS)). In one embodiment, the polymixin antibacterial agent is colistin, suitably colistin methanesulfonate sodium.
Polymixin antibacterial agents target Gram-negative bacteria and exhibit antibacterial activity by binding to the lipopolysaccharide in the outer membrane of the bacteria, disrupting both the outer and inner membranes, leading to leakage of the intracellular contents and bacterial cell death.
The most common adverse effect of colistin treatment is nephrotoxicity (renal toxicity) because the drug is excreted primarily by the kidneys and elevated blood levels may further impair renal function. However, the use of more purified colistin, the use of colisin methanesulfonate sodium instead of colistin sulphate, more adequate does adjustment according to renal function and significant improvement of ICU monitoring and treatment has resulted in a relatively lower incidence of renal toxicity (Spapen et al., Annals of Intensive Care 201 1 , 1 :14, 1 -7). The interaction of colistin with neurons, which have high lipid content, has been associated with the occurrence of peripheral and orofacial paresthesias, vertigo, mental confusion, ataxia and seizures. However, a review by Spapen et al. concluded that neurotoxicity was not a major adverse event accompanying colistin treatment (Annals of Intensive Care 201 1 , 1 :14, 1 -7).
Glycylcyclines
Glycylcycline antibacterial agents are broad spectrum antibacterial agents that were developed as tetracycline analogues in order to overcome tetracycline resistance. This structural class of antibacterial agents is bacteriostatic, and act by binding to the bacterial 30S ribosomal subunit and by blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. Amino acid residues are prevented from becoming incorporated into elongating peptide chains, which leads to inhibition of protein synthesis.
The only glycylcycline antibacterial agent presently available for clinical use is tigecycline, which is available only as an injectable formulation. Thus, in one embodiment, the glycylcycline antibacterial agent is tigecycline. According to a review by Noskin, G.A. (Clinical Infectious Diseases 2005, S303-14) tigecycline has shown promise as a monotherapy and its use as part of a combination regimen has not been evaluated.
Rifampicin
Rifampicin is a bactericidal antibacterial agent of the rifamycin group and is typically used to treat Mycobacterium infections including tuberculosis and Hansen's disease. Rifampicin inhibits bacterial DNA-dependent RNA synthesis by inhibiting bacterial DNA-dependent RNA polymerase. The most serious adverse effect of administering rifampicin is hepatotoxicity.
Sulbactam
Sulbactam is a β-lactamase inhibitor which is typically administered in combination with a β-lactam antibiotic, β-lactamases are enzymes which degrade β-lactam antibiotics, therefore when sulbactam binds to the enzyme it prevents degradation of the β-lactam antibiotic.
In one embodiment, the antibacterial agent in combination with compound (I) is selected from the group consisting of meropenem, imipenem, amikacin, gentamicin, tobramycin, colistin, tigecycline, rifampicin and sulbactam and is suitably selected from the group consisting of meropenem, amikacin and colistin.
Microbial pathogens
As illustrated in the Examples, novel combinations of compound (I) with certain known antibacterial agents have potential utility for treating infection by microbial pathogens.
Thus, in one embodiment, the antibacterial combinations of the present invention can be used to treat microbial infection in humans and animals. Antibacterial combinations of the present invention are particularly useful in forming a therapeutic regimen having a selective spectrum of activity in vitro and in vivo against bacterial strains relying on Fabl and related targets.
Such strains encompass Staphylococcus aureus including multiresistant strains (such as methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin- resistant Staphylococcus aureus (VRSA) strains), Acinetobacter strains (such as Acinetobacter baumannii), Bacillus anthracis, Chlamydophila pneumoniae, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Neisseria meningitidis and also bacteria such as Mycobacterium tuberculosis carrying homologous Fabl enzymes such as InhA or other organisms such as Plasmodium falciparum.
In one embodiment, the antibacterial combination of the present invention is used in the treatment of human or animal microbial infection by Acinetobacter, in particular Acinetobacter baumannii.
Acinetobacter
There are five different phylogenetic Acinetobacter groups involved in human infections: A. baumannii (most frequent), A. nosocomialis, A. pitii, A. calcoaceticus, and the fifth group has been only recently identified and has yet to be named (Nemec A., 2013, 9th International Symposium on the Biology of Acinetobacter).
While all Acinetobacter groups can potentially cause human disease, A. baumannii accounts for about 80% of reported Acinetobacter infections
(http://www.cdc.gov/HAI/organisms/acinetobacter.html) A. baumannii is an emergent nosocomial pathogen which has also been isolated from soil and water samples in the environment, although infection rarely occurs outside of healthcare settings. Risk factors associated with A. baumannii include prolonged hospitalization, intensive care unit admission, invasive surgical procedures, previous treatment with antibiotics (such as imipenem and levofloxacin), chronic lung disease and alcoholism (Seifert H., 2013, 9th International Symposium on the Biology of Acinetobacter).
Acinetobacter causes a variety of diseases including blood stream infections, urinary tract infections, meningitis, wound infections especially in burns patients (Dijkshoorn L, 2013, 9th International Symposium on the Biology of Acinetobacter), and pneumonia especially in patients on mechanical ventilation. Acinetobacter may also colonize in a patient without causing infections or symptoms, especially in tracheostomy sites or open wounds (http://www.cdc.gov/HAI/organisms/acinetobacter.html). Acinetobacter can be spread by person-to-person contact, airborne transmission, environmental surfaces and medical equipment (Seifert H., 2013, 9th International Symposium on the Biology of Acinetobacter).
Thus, in one embodiment the infection by A. baumannii is associated with a disease or disorder selected from the group consisting of a blood stream infection, a urinary tract infection, meningitis, a wound infection (especially in a burns patient) and pneumonia (especially in a patient on mechanical ventilation).
As shown in the checkerboard studies of Example 3, over 70% of the combinations of compound (I) and an additional antibacterial agent as defined herein exhibited additivity and/or synergy, with colistin in particular demonstrating synergy with compound (I). In Example 4, sub- MIC combinations of compound (I) and amikacin and meropenem were found to exhibit bactericidal activity (i.e. time to attain 99.9% bacterial killing, which is defined as a A3log10 reduction compared to initial inoculum).
In vivo studies (Example 6) using a mouse model of A. baumannii pneumonia demonstrated that administering combinations of compound (I) with amikacin and meropenem increased survival rates compared with administering amikacin and meropenem alone. A combination of compound (I) and colistin demonstrated greater efficacy than compound (I) alone.
Pharmaceutical composition
The combination of compound (I) and the additional antibacterial agent can be co-formulated as a pharmaceutical composition. Thus, in one embodiment, there is provided a pharmaceutical composition comprising:
(a) 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide (compound (I)); and
(b) an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
Alternatively, compound (I) and the additional antibacterial agent can be formulated as separate pharmaceutical compositions.
Thus, in one embodiment, there is provided a kit of parts comprising:
(a) a pharmaceutical composition comprising 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide; and
(b) a pharmaceutical composition comprising an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
Said kit of parts will typically be accompanied by instructions specifying the co-administration of (a) and (b).
Such pharmaceutical compositions (co-formulated or separate) can be formulated to be administered under oral, topical, parenteral including injectable routes, such as intravenous administration, with individual doses appropriate for the patient to be treated.
Suitably, compound (I) is not administered orally. Suitably, compound (I) is formulated to be administered via parenteral routes. Compound (I) and the additional antibacterial agent will typically be formulated for administration via the same route, thus in one embodiment
compound (I) and the additional antibacterial agent are both formulated for administration via parenteral routes. However, compound (I) and the additional antibacterial agent need not be formulated for administration via the same route. For example, compound (I) may be formulated for administration via parenteral routes and the additional antibacterial agent formulated for oral administration.
The compositions according to the invention can be solid, liquid or in the form of a gel/cream and be present in the pharmaceutical forms commonly used in human medicine, such as for example, plain or sugar-coated tablets, gelatin capsules, granules, suppositories, injectable preparations, ointments, creams, gels; they are prepared according to the customary methods. The active ingredient/s can be incorporated using excipients which are customarily used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting agents, dispersants or emulsifiers, preservatives. These compositions can also be present in the form of a powder intended to be dissolved extemporaneously in an appropriate vehicle, for example, non-pyrogenic sterile water.
In one embodiment, the pharmaceutical composition additionally comprises a solubilisation agent.
In one embodiment, the pharmaceutical composition additionally comprises an isotonic agent.
In one embodiment, the pharmaceutical composition additionally comprises a diluent. In a further embodiment, the diluent comprises water, such as QS water.
Modes of administration
Suitably, compound (I) and the additional antibacterial agent are administered via the same route of administration. Suitably, compound (I) and the additional antibacterial agent are both administered intravenously. As discussed above, compound (I) may be co-formulated with the additional antibacterial agent, or formulated separately. Suitably, compound (I) is formulated separately from the additional antibacterial agent, but both compound (I) and the additional antibacterial agent are administered intravenously.
In the methods and uses of the invention compound (I) and the additional antibacterial agent are administered as a combination, i.e. they are co-administered. The co-administration may occur simultaneously or sequentially.
In one embodiment, compound (I) and the additional antibacterial agent are administered simultaneously. Simultaneous administration can involve the co-formulation of compound (I) and the additional antibacterial agent. Alternatively, compound (I) and the additional antibacterial agent can be formulated separately, but administered to the patient at the same time. Suitably, compound (I) and the additional antibacterial agent will be administered simultaneously, via separate or the same parenteral routes.
In one embodiment, compound (I) and the additional antibacterial agent are administered sequentially. In one embodiment, compound (I) is administered prior to the additional antibacterial agent. In another embodiment, the additional antibacterial agent is administered prior to compound (I). In a therapeutic regimen comprising sequential administration either:
1 . compound (I) is administered to a subject, then after a period of time the additional antibacterial agent is administered to the subject; or
2. the additional antibacterial agent is administered to a subject, then after a period of time compound (I) is administered to the subject.
The period of time between administration of the two agents (i.e. the period of time referred to at point 1 . or 2., above) may be up to 12 hours, for example up to 1 1 hours, up to 10 hours, up to 9 hours, up to 8 hours, up to 7 hours, up to 6 hours, up to 5 hours, up to 4 hours, up to 3 hours, up to 2 hours, up to 1 hour, up to 50 minutes, up to 45 minutes, up to 30 minutes, up to 25 minutes, up to 20 minutes, up to 15 minutes, up to 10 minutes, up to 9 minutes, up to 8 minutes, up to 7 minutes, up to 6 minutes, up to 5 minutes, up to 4 minutes, up to 3 minutes, up to 2 minutes, up to 1 minutes or up to 30 seconds.
The combination of compound (I) and the additional antibacterial agent (whether via simultaneous or sequential administration) may be administered as a daily dosage, or may be administered at more frequent intervals such as twice daily. Treatment should be continued for as long as required to receive the benefit of the invention.
The absolute and relative dosages of compound (I) and the additional antibacterial agent will depend on the nature of the additional antibacterial agent.
In one embodiment, the dosage of compound (I) in the combination will be lower than the MIC of compound (I) when administered as a monotherapy.
In one embodiment, the dosage of the additional antibacterial agent in the combination will be lower than the MIC of the additional antibacterial agent when administered as a monotherapy.
In one embodiment, the individual dosages of compound (I) and the additional antibacterial agent in the combination will both be lower than their respective MICs when administered as a monotherapy.
Typically, the dosage of compound (I) in the combination will be between about 1000 mg/kg and about 0.1 mg/kg, such as between about 800 mg/kg and about 1 mg/kg, between about 500 mg/kg and about 10 mg/kg or between about 300 mg/kg and about 100 mg/kg, such as about 200 mg/kg.
If the additional antibacterial agent is a carbapenem, typically the dosage of carbapenem will be between about 1000 mg/kg and about 0.1 mg/kg, such as between about 800 mg/kg and about 1 mg/kg, between about 500 mg/kg and about 10 mg/kg, or between about 150 mg/kg and about 10 mg/kg, such as about 50 mg/kg.
Thus, in one embodiment an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 50 mg/kg of a carbapenem, dosed simultaneously or sequentially.
If the additional antibacterial agent is an aminoglycoside such as amikacin, typically the dosage of aminoglycoside will be between about 1000 mg/kg and about 0.1 mg/kg, such as between about 800 mg/kg and about 1 mg/kg, between about 500 mg/kg and about 5 mg/kg or between about 50 mg/kg and about 5 mg/kg, such as about 18 mg/kg.
Thus, in one embodiment an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 18 mg/kg of an aminoglycoside, dosed simultaneously or sequentially.
If the additional antibacterial agent is a polymixin such as colistimethate sodium, typically the dosage of polymixin will be between about 1000 mg/kg and about 0.1 mg/kg, such as between about 800 mg/kg and about 0.1 mg/kg, between about 500 mg/kg and about 0.5 mg/kg, between about 50 mg/kg and about 0.5 mg/kg, or between about 10 mg/kg and about 1 mg/kg, such as about 5 mg/kg.
Thus, in one embodiment an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 5 mg/kg of polymixin, dosed simultaneously or sequentially.
If the additional antibacterial agent is a glycylcycline such as tigecycline, typically the dosage of glycylcycline will be between about 1000 mg/kg and about 0.1 mg/kg, such as between about 800 mg/kg and about 0.1 mg/kg, between about 500 mg/kg and about 0.1 mg/kg, or between about 300 mg/kg and about 0.1 mg/kg, such as about 1 -2 mg/kg.
Thus, in one embodiment an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 2 mg/kg of glycylcycline, dosed simultaneously or sequentially.
If the additional antibacterial agent is rifampicin, typically the dosage of rifampicin will be between about 1000 mg/kg and 0.1 mg/kg, such as between about 800 mg/kg and 1 mg/kg, or between about 600 mg/kg and about 1 mg/kg, such as about 20 mg/kg.
Thus, in one embodiment an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 20 mg/kg of rifampicin, dosed simultaneously or sequentially.
If the additional antibacterial agent is sulbactam, typically the dosage of sulbactam will be between about 300 mg/kg and about 1 mg/kg, such as between about 150 mg/kg and about 1 mg/kg, or between about 100 mg/kg and about 10 mg/kg, such as about 50 mg/kg.
Thus, in one embodiment an adult dosage regimen comprises a dose of 200 mg/kg of compound (I) and 50 mg/kg of sulbactam, dosed simultaneously or sequentially.
Abbreviations
LP. intra peritoneal
MIC minimum inhibitory concentration*
CFU colony-forming unit
FIC fractional inhibitory concentration
AMK amikacin
AMK-R amikacin-resistant
MPM meropenem
MPM-R meropenem-resistant
COL colistin
COL-R colistin-resistant
Sus susceptible
PVP polyvinylpyrrolidone
*Minimum inhibitory concentration as used herein refers to the lowest concentration of an antibacterial agent that will inhibit the visible growth of a bacterial strain after overnight incubation.
EXAMPLES
Materials
Clinical isolates - in vitro Examples 2, 3 & 4
In the antimicrobial susceptibility testing 77 isolates of A. baumannii (from 2010) in the following sub-groups were tested:
22 isolates generally susceptible to antimicrobial agents ("Sus")
20 carbapenem-resistant isolates (e.g. "MPM-R")
20 aminoglycoside-resistant isolates (e.g. "AMK-R")
15 colistin-resistant isolates, (e.g. "COL-R")
Checkerboard interaction studies were performed using 5 isolates from each of the sub-groups and time kill studies were performed using 3 isolates from each sub-group.
Antimicrobial agents - in vitro Examples 2, 3 & 4
Compound (I) was prepared in-house according to the method described in Example 1 . Amikacin, tobramycin, meropenem, colistin and gentamicin were all obtained from Sigma.
General Procedures
Individual antimicrobial susceptibility testing - Example 2
Minimum inhibitory concentration (MIC) endpoints were determined by broth microdilution according to CLSI guidelines (CLSI, M7-A8 & M100-S22, 2012). Panels were prepared at IHMA using cation-adjusted Mueller-Hinton broth. Colonies were taken directly from a second- pass culture plate and prepared to a suspension equivalent of the 0.5 McFarland standard using normal saline. Inoculation of the MIC plates took place within 15 minutes after adjustment of the
inoculum suspension turbidity. The panels were incubated at 35 °C for 20-24 hours before reading the MIC endpoints.
Checkerboard testing (compound (I)/ 'antibacterial agent interaction)
Checkerboards (20 isolates, 5 per sub-group) were prepared so as to contain multiple concentrations of compound (I) with different additional antibacterial agents (amikacin, gentamicin, colistin, meropenem and tobramycin) as follows:
Serial two-fold dilutions of the antimicrobial agents alone or in combination in wells of 96 well microtiter plates were inoculated with the appropriate inoculum so that each well contained approximately 4 - 5 x 104 CFU/ml. Plates were incubated at 35°C for 16 - 20 hours. Combination concentrations were tested between 0.25 x MIC and 2 x MIC. Growth and sterility controls were also included in each plate.
Synergy, indifference and antagonism were calculated based upon the use of the fractional inhibitory concentration (FIC) indices as described by Pillai, Moellering & Eliopoulos (2005) whereby:
Synergism = FIC index of < 0.5 Indifference = FIC index > 1 but < 4 Additivity >0.5 to 1 Antagonism = FIC index of > 4
Time kill study - Example 4
A total of 12 isolates were tested (three per sub-group either susceptible, meropenem-resistant, amikacin-resistant or colistin-resistant). Two combinations were tested per isolate. Time-kill kinetics were performed by testing compound (I) and an additional antibacterial agent (amikacin, colistin and meropenem) individually at 1 x and 4x the corresponding MIC of each antibacterial agent. In addition, a second set of experiments involved the testing of compound (l)/additional antibacterial agent combinations of 0.25x/0.25x, 0.5x/0.5x, 1 x/1 x, and 4x/4x MIC. Samples were taken at 0, 2, 4, 8 and 24 hours in order to determine colony forming units (CFU/mL). Bactericidal activity is defined by a reduction of the inoculum by 3 Iog10 compared to initial inoculum at a defined time point (CLSI M26A, 1999).
Example 1 - Preparation of 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide (compound (I))
Compound (I) may be prepared using the procedures outlined in international application WO 201 1/026529. The procedure corresponding to "Example 1 (Alternative Procedure)" of WO 201 1/026529 is outlined below:
Compound X Compound (I)
Compound X (disclosed as Intermediate 3 in WO 201 1/026529) in acetonitrile was partially distilled under atmospheric pressure to 6.4 residual volumes. 7 volumes of acetic acid were then added and the solution was distilled under atmospheric pressure to 6.4 residual volumes. One additional volume of acetic acid was added and the solution was distilled again under atmospheric pressure to 6.4 residual volumes. Sulphuric acid (6 volumes total) was added and the reaction mixture was stirred at 120 °C for 5 hours.
Once the reaction was complete, the temperature was lowered to 20 °C, dichloromethane (10 volumes) and water (8 volumes) were added. At this temperature, clarcel® (0.5 parts) and charcoal (0.5 parts) were also added and the resulting mixture was stirred for 30 min. The mixture was filtered and the intermediate cake washed three times with 2 volumes of dichloromethane each time. The resulting phases were separated and the aqueous phase was back extracted twice with 3 volumes of dichloromethane. The combined organic phases were partially distilled under atmospheric pressure to 14.5 residual volumes and methylcyclohexane (22 volumes) was added at 37°C ± 2°C. To this solution was added sodium bicarbonate (10%) (1 volume). Instantaneous crystallization was observed. The slurry was cooled down to 0°C, filtered, washed twice with 2 volumes of methylcyclohexane at RT and dried at 40 °C under vacuum to afford the crude 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide.
The crude 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide was dissolved in 7 volumes of isopropanol and 1 volume of water at 60 °C to carry out a filtration on a zetacarbon cartridge. The cartridge was then washed twice with 1 volume of isopropanol. Water (12.5 volumes) was added to this solution and the mixture was cooled down at 10°C/h to 5°C. The product was filtered, washed twice with water (2 volumes each time) at RT and dried under vacuum at 70 °C to afford the pure 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide (title compound) in 36.5% overall yield in 99.6% HPLC purity.
Example 2 - Individual antimicrobial susceptibility testing
Testing was carried out as described in the General Procedures to determine minimum inhibitory concentration (MIC) end points for compound (I), amikacin, colistin, gentamicin, meropenem and tobramycin, for 77 A. baumannii isolates. Under the "MIC ^g/ml)" heading, the first column (Range) indicates the MIC end points for the particular number (N) of isolates tested, the second column (50%) provides an estimate of the concentration that inhibits 50% (MIC50) of bacterial isolates tested, and the third column (90%) provides an estimate of the concentration that inhibits 90% of the bacterial isolates tested.
Compound (I) exhibited good activity against the majority of the 77 isolates tested in this study with MICs ranging from 0.5-8, 2-8, 0.25->32 and 2->32 μg/ml against susceptible, amikacin-R, colistin-R and meropenem-R isolates respectively. Although the overall MIC range was quite broad, the majority of Compound (I) MICs were in the range of 2-8 μg/ml. The mode MIC was 4 μg/ml (Figure 1 ).
The MIC distributions for compound (I), amikacin, colistin, gentamicin, meropenem and tobramycin are shown in Figure 2. This Figure shows that colistin had the lowest mode MIC,
followed by tobramycin and compound (I). The isolates resistant to amikacin, gentamicin, tobramycin and meropenem can be seen to the right of Figure 2 (MIC >32 μg ml). Summary MIC data are given in Table 1.
Table 1 - Summary of MIC data
* number of isolates
Example 3 - Checkerboard testing
Checkerboard studies were carried out as described in General Procedures using twenty different A. baumannii isolates with 5 per sub-group of: susceptible, amikacin-resistant, colistin- resistant and meropenem-resistant. Combinations of compound (I) with amikacin, colistin, gentamicin, meropenem and tobramycin were tested against the different isolates and the results are set out below in Tables 2-5 and are summarised in Figure 3.
Table 2: checkerboard interaction studies with compound (I) and additional antibacterial agents against susceptible isolates of A. baumannii
(I) = compound (I); add. agent = additional antibacterial agent
Table 3: checkerboard interaction studies with compound (I) and additional antibacterial agents against amikacin-resistant isolates of A. baumannii
(I) = compound (I); add. agent = additional antibacterial agent
Table 4: checkerboard interaction studies with compound (I) and additional antibacterial agents against colistin-resistant isolates of A. baumannii
(I) = compound (I); add. agent = additional antibacterial agent
Table 5: checkerboard interaction studies with compound (I) and additional antibacterial agents against meropenem-resistant isolates of A. baumannii
(I) = compound (I); add. agent = additional antibacterial agent
Conclusion
None of the combinations of compound (lyadditional antibacterial agent tested exhibited antagonism and only 19% exhibited indifference. Irrespective of the resistance phenotypes, compound (lyadditional antibacterial agent combinations assessed resulted in synergy or additivity in 81 % of combinations (additivity in 64% of combinations and synergy in 17% of
combinations). The best effect was shown with compound (I) combined with colistin where 65% of the combinations were synergistic.
Example 4 - Time kill kinetics - bactericidal effects against various A. baumannii isolates
Time-kill studies were carried out as described in General Procedures using combinations of compound (I) with amikacin, meropenem and colistin, respectively.
The bactericidal effects of compound (I) in combination with amikacin (AMK) against various A.baumannii isolates (phenotypes) are illustrated in Figures 4-9 and summarised in Table 6.
Table 6
Time to kill 99.9%
A3logio reduction compared to initial inoculum
ALONE IN COMBINATION
AMK/ AMK/ AMK/ AMK/
MIC (Mg/mL) (1) (1) AMK AMK
(1) (1) (1) (1)
0.25x / 0.5x /
Phenotype (1) AMK "I xMIC 4xMIC "I xMIC 4xMIC 1 x/1 x 4x/4x
0.25x 0.5x
Sus-1 1 2 >24h >24h 1.7h* 1.2h >24h 3h* 1.8h 1.4h
Sus-2 2 4 >24h >24h ND 1.2h 6.8h* 3.5h 2.3h 1.2h
Sus-3 8 4 >24h >24h 1.3h 1.3h 3.1 h* 2.2h 1.4h 1.3h
MPM-R-1 8 4 >24h >24h 1.4h* 1.2h 3.8h* 2.1 h* 1.5h 1.2h
MPM-R-2 4 8 >24h >24h 1.3h 1.2h 4.7h* 1.8h* 1.4h 1.2h
MPM-R-3 4 4 >24h >24h 1.4h* 1.2h 2.6h* 1.8h 1.4h 1.2h
*A3Logio kill observed during 24 hour experimental period though re-growth also observed.
Sub-MIC combinations that resulted in A3Loqio kill Sus = susceptible; MPM-R = meropenem-resistant
(1) = Compound (I); AMK = Amikacin ND, not determined
The bactericidal effects of compound (I) in combination with meropenem (MPM) against various A.baumannii isolates (phenotypes) are illustrated in Figure 10-15 and summarised in Table 7.
Table 7
Time to kill 99.9%
A3logio reduction compared to initial inoculum
ALONE IN COMBINATION
MPM/ MPM/ MPM/ MPM/
MIC (Mg/mL) (1) (1) MPM MPM
(1) (1) (1) (1)
0.25x / 0.5x /
Phenotype (1) MPM I xMIC 4xMIC I xMIC 4xMIC 1 x/1 x 4x/4x
0.25x 0.5x
AMK-R-1 4 4 >24h >24h 5.2h* 3.2 6.5h* 4.3h 3.2h 2.7h
AMK-R-2 4 16 >24h >24h >24h 6.1 h >24h 7.2h* 4.9h 4.4h
AMK-R-3 2 16 >24h >24h 3.6h 1.8h 6.3h 3.9h 3.7h 3.5h
COL-R-1 8 64 >24h >24h 3.6h 3.6h >24h 3.5h 3.0h 1 1.3h
COL-R-2 4 0.25 >24h >24h >24h 5.8h* >24h >24h 12.8h 6.8h
I COL-R-3 I 16 I 6 I >24h >24h | >24h 3.2h | >24h 5.9h | 5.4h 5.6h
*A3Logio kill observed during 24 hour experimental period though re-growth also observed
Sub-MIC combinations that resulted in A3Loqio kill AMK-R = amikacin-resistant; COL-R = colistin-resistant
(1) = Compound (I); MPM = meropenem
The bactericidal effects of compound (I) in combination with colistin (COL) against various
A.baumannii isolates (phenotypes) are illustrated in Figures 16-27 and summarised in Table 8.
Table 8
Time to kill 99.9%
A3logio reduction compared to initial inoculum
ALONE IN COMBINATION
COL/ COL/ COL/ COL/
MIC (Mg/mL) (1) (1) COL COL
(1) (1) (1) (1)
0.25x / 0.5x /
Phenotype (1) COL 1 xMIC 4xMIC 1 xMIC 4xMIC 1 x/1 x 4x/4x
0.25x 0.5x
Sus-2 2 0.5 >24h >24h 6.3h >24h >24h >24h 6.5h
Sus-1 1 1 >24h >24h >24h >24h >24h 7.0h* 7.2h >24h
Sus-3 8 0.25 >24h >24h 1.6h* 3.6h >24h >24h >24h 12.0h
MPIV1-R-1 8 0.25 >24h >24h 5.0h* 8.1 h >24h >24h 15.1 h 14.7h
MPM-R-1 4 1 >24h >24h 1.3h* 1.6h* >24h >24h 9.6h 4.7h
MPM-R-3 4 1 >24h >24h 2h 5.1 h >24h 19.4h 5.6h 9.8h
AMK-R-1 4 0.5 >24h >24h 1.4h* 1.3h* >24h >24h 23.5h 2.8h
AMK-R-2 4 0.5 >24h >24h 2.3h* 1.8h >24h >24h >24h 4.3h
AMK-R-3 2 0.25 >24h >24h >24h 2.9h* >24h >24h >24h >24h
COL-R-1 8 8 >24h >24h 2.8h* 2.3h >24h >24h 1 1.4h 5.0h
COL-R-2 4 4 >24h >24h >24h >24h >24h >24h >24h 13.7h
COL-R-3 16 16 >24h >24h 2.7h* 2.1 h* >24h 13.9h 4.7h 1.5h
*A3Log-io kill observed during 24 hour experimental period though re-growth also observed.
Sub-MIC combinations that resulted in A3Loqio kill.
Sus = susceptible; MPM-R = meropenem-resistant; COL-R = colistin-resistant
(1) = Compound (I); COL = colistin
In time-kill studies, compound (I) when tested alone at either 1 x or 4x MIC was bacteriostatic.
The additional antibacterial agents, amikacin, meropenem and colistin, were generally bactericidal (≥99.9% bacterial killing) against the majority of isolates when tested at 4x MIC and against many isolates when tested at 1 x MIC.
In general, compound (I) 4x/additional antibacterial agent 4x MIC combinations resulted in the same effects as when the comparator was tested alone. This also held true for compound (I) 1 x/additional antibacterial agent 1 x MIC combinations though not for all isolates tested.
A most interesting finding was observed for sub-MIC combinations (0.25x / 0.25x MIC and 0.5x/0.5x MIC) of compound (l)/amikacin or meropenem, whereby against the majority of the isolates tested, these sub-MIC concentrations tested exhibited bactericidal (time to attain 99.9%
bacterial killing) activity (91.6% of amikacin experiments and 58.3% of meropenem experiments).
The combination of compound (l)/colistin at sub-MIC was bactericidal in 12.5% of experiments in this study.
Conclusion - in vitro studies
In a study of activity in a panel of 77 isolates of A. baumannii, compound (I) exhibited good activity against the majority of the 77 isolates tested. Although the overall MIC range was quite broad, the majority of MICs were in the range of 2-8 μg ml.
Checkerboard studies resulted in 81 % of combinations demonstrating additivity or synergy, with combinations of compound (I) and gentamicin, meropenem and tobramycin demonstrating synergy against certain amikacin-resistant and colistin-resistant strains of A. baumannii and the combination of compound (I) with colistin resulted in 65% synergistic activity, against many susceptible, amikacin-resistant, colistin-resistant and meropenem-resistant strains of A. baumannii.
In a study of in vitro time kill in a panel of 20 isolates of A. baumannii, compound (I) when tested alone at 1x and 4x MIC was bacteriostatic, but sub-MIC combinations of compound (l)/amikacin or compound (l)/meropenem (0.25x/0.25x MIC and 0.5x/0.5x MIC) exhibited bactericidal activity against the majority of the 20 isolates tested. Despite the strong synergy demonstrated with the combination of compound (I) and colistin in the checkerboard experiments, a weaker interaction was observed in this particular study.
Example 5 - Further in vitro study
Following on from the promising results of the in vitro experiments of Examples 2, 3 and 4, a smaller-scale in vitro study was carried out using the A. baumannii strains used in the in vivo mouse model study (Example 6).
Materials
Antimicrobial agents
Compound (I) was supplied by NOVASEP-FINORGA. Methanol was added to 5 mg of compound (I) in order to obtain a 20 mg/mL solution.
Amikacin was supplied by MYLAN LAB. A solution containing 50 mg/mL of amikacin was diluted in saline solution and used immediately after dilution in order to obtain a concentration of 1.8 mg/mL.
Meropenem was supplied by ASTRA ZENECA as Meronem®. A solution containing 50 mg/mL of meropenem was diluted in saline solution and used immediately after dilution in order to obtain a concentration of 5 mg/mL.
Colistin was supplied by SANOFI-AVENTIS as Colimycine®. 3 mL of saline solution was added onto 33.33 mg of colistin powder in order to obtain a 1 1.1 1 mg/mL solution.
A. baumanni isolates
A. baumannii CIP 5377 (ATCC® 17978): low cephalosporinase producing strain, susceptible to meropenem and amikacin, isolated in an infected patient
A. baumannii CIP 7034: low cephalosporinase producing strain, susceptible to meropenem and amikacin
A. baumannii AYE ATCC® BAA1710™: extended spectrum beta-lactamase producing strain susceptible to meropenem and resistant to amikacin
A. baumannii SAN-94040 (SAN): cephalosporinase-overproducing strain, susceptible to meropenem and intermediate to amikacin and resistant to fluoroquinolones, isolated from blood cultures of an intensive care patient with nosocomial pneumonia from North Africa (Algeria). A. baumannii RCH-69: cephalosporinase producing strain; low susceptibility to imipenem and resistant to amikacin.
Antimicrobial Susceptibility Testing (MIC determination)
Minimum inhibitory concentration (MIC) endpoints were determined by broth microdilution methodology in a 96-well microplate after incubation for 24 hours at 37°C according to the recommendations of EUCAST. The MICs results are given in Table 9:
Table 9: MIC data of compound (I) and comparator antibacterial agents
Compound (I) exhibited good activity against the 5 isolates of A. baumannii tested in this study with MICs ranging from 1 to 2 μg mL against susceptible, amikacin-R and meropenem-R isolates.
Bactericidal Activity (Time Kill Kinetics)
Time-kill kinetics were performed at 37°C by testing compound (I) and selected antimicrobial agents individually at 2x the corresponding MIC of each antibacterial agent. In addition, a second set of experiments involved the testing of compound(l)/additional antibacterial agent combinations of 2x/2x MIC. Samples were taken at 0, 3, 6 and 24 hours in order to determine colony forming units (CFU/mL). Bactericidal activity was defined by a reduction of the inoculum by 3 Iog10 compared to initial inoculum (105 CFU/mL) at a defined time point (CLSI M26A, 1999).
In this time-kill study, compound (I) was observed to be bacteriostatic when tested alone at 2x MIC. The additional antibacterial agents amikacin and meropenem were observed to be bactericidal when tested alone at 2x MIC.
Combinations of compound (I) and either amikacin or meropenem (with all antibacterial agents at 2x their respective MIC) resulted in synergy as shown in Figure 28, thereby confirming the results of Example 4.
Example 6 - Mouse model of A. baumannii infection
The aim of this study was to investigate the efficacy of co-administration of compound (I) with amikacin, meropenem or colistin, in a mouse model of A. baumannii pneumonia infected via the intra-tracheal route.
Materials
Compound (I) was supplied as a nanosuspension, prepared by wet milling as follows.
The milling medium was prepared by dissolving a polymer, PVP (polyvinylpyrrolidone)! 2PF (Kollidon 12 PF, BASF), at 50.0 mg/mL in purified water at 50 mL scale. The solution was added to a 250 mL clear glass vial (Type II), followed by addition of compound (I) at 100 mg/mL. To avoid aggregation, immediately after compounding a pre-suspension was made by stirring using a magnetic stirrer for 30 minutes. Finally, the milling beads were added. 225 g of ytrium stabilized zirconium oxide beads with a diameter of 0.5 mm were added. The vial was closed and placed on a roller mill (Peira, Beerse, Belgium) for the wet milling process. The vial speed was set at 160 rpm (setting 600). After 64 hr of wet milling a sample was taken for analysis of particle size distribution using laser diffraction, type Mastersizer 2000 (Malvern, Worcestershire, UK) to confirm that at least 90% of the suspended particles were inferior to 500 nm in diameter and the milling process was stopped. The white homogeneous nanosuspension was then harvested from the milling beads using a syringe with a 23G needle.
The particular composition of the nanosuspension used in each study is described in the relevant "Study design" section.
Two strains of A. baumannii were used.
SAN-94040 (SAN): cephalosporinase-overproducing strain, susceptible to meropenem and intermediate to amikacin and resistant to fluoroquinolones, isolated from blood cultures of an intensive care patient with nosocomial pneumonia from North Africa (Algeria). The SAN strain is responsible for an average of 80% mortality rate in this mice pneumonia model.
RCH-69: cephalosporinase producing strain; low susceptibility to imipenem and resistant to amikacin.
Test System and Infection Establishment
The bacterial inoculum was prepared in order to obtain a suspension containing 108 CFU/mL of Acinetobacter baumannii in saline.
Experimentations were performed with six-week old female C3H/HeN mice (18-20 g, Breeding Centre JANVIER (lie saint Genest Mayenne 53)) because of their particular susceptibility to Acinetobacter baumannii and the reproducibility of the results (inbreeding in the breed). Each mouse was individually marked and housed in cages containing five animals/cage under ventilated and controlled (temperature and humidity) atmosphere.
The mice were rendered transiently neutropenic by 2 intra-peritoneal (IP) injections of 150 μΙ_ of cyclophosphamide (Endoxan® 150 mg/kg) 4 (D-4) and 3 (D-3) days before the Acinetobacter baumannii inoculation (Day 0). This transient immunosuppression was sufficient to facilitate the development of the A. baumannii pneumonia while allowing the recovery of the neutrophil influx 2 (Day 2) days after inoculation in order to avoid or limit a systemic bacterial dissemination.
Mice were anesthetized by a mixture of oxygen and isoflurane. The bacterial inoculation was performed on Day 0 by intra-tracheal installation using an endotracheal catheter (50μΙ of the suspension, thus 5.106 CFU). The positioning of the catheter in the trachea (instead of in the oesophagus) was checked by a "ring test". The bacterial count in lungs was checked for all study groups by sacrificing one mouse immediately after inoculation.
In vivo end points Survival rate
Survival observations were assessed twice daily, up to 4 days post infection.
The survival rates were compared with the Chi-square test or the Fisher exact test as appropriate. The survival curves were compared by the Kaplan-Meier method.
Bacterial Count in Blood and Tissues
Sample time points: TO (pre-inoculation), T24h (post inoculation), T48h and T72h.
Blood samples preparation: At each time point, three mice were sacrificed per group by cervical dislocation.
Tissue samples preparation: At each time point, three mice were sacrificed per group. Lungs, kidneys, liver and spleen were collected after the blood sampling and cervical dislocation. Tissues were wiped with a sterile gauze to remove blood contaminant outside. Tissues were then be weighed, finely ground and plated on agar for quantitative culture. Cultures were incubated at 37°C for 18 to 24 hours.
Statistical analysis
Student's t test, X2 or Kruskal Wallis test was used to compare the CFU counts.
The survival rates were be compared with the Chi-square test or the Fisher exact test as appropriate.
The survival curves were compared by the Kaplan-Meier method.
P<0.05 was be considered statistically significant.
Three studies were carried out as follows:
Study 1
The aim of this experiment was to assess the survival rate of transiently neutropenic female C3H/HeN mice administered, 3 hours post-inoculation of A. baumannii SAN-94040 via intratracheal route, with compound (I) via intra-peritoneal route at 200 mg/kg 3 times daily (every 8
hours) for 1 day alone and in combination with meropenem at 50 mg/kg 3 times daily (every 8 hours) for 1 day or with amikacin at 18 mg/kg 3 times daily (every 8 hours) for 1 day. 84 mice were allocated into 6 groups as shown in Table 10.
The SAN-94040 strain of A. baumannii is susceptible to meropenem and has intermediate susceptibility to amikacin.
Table 10: Study 1 design
* number of mice
Three vials of 8 mL each containing 91.6 mg of compound (l)/mL and 45.8 mg of PVP 12PF (Kollidon 12PF)/mL were prepared and stored between +02°C and +08°C. Following storage, each vial was homogenized by manual shaking and diluted by 2-fold in 16.17 mg/mL NaCI aqueous solution in order to obtain a 45.8 mg of compound (l)/mL isotonic suspension.
In Group 2 (compound (I) alone), mice were administered with 200 μί of a 20 mg/mL compound (I) suspension obtained by diluting 2.183 mL of the 45.8 mg/mL suspension in 2.817 mL of 0.9% NaCI aqueous solution.
In Groups 5 and 6 (compound (I) in combination with amikacin and meropenem, respectively), mice were administered with 100 μί of a 40 mg/mL compound (I) suspension obtained by diluting 4.367 mL of the 45.8 mg/mL suspension in 0.683 mL of 0.9% NaCI aqueous solution.
Meropenem was supplied by ASTRA ZENECA (Meronem®) (50 mg of meropenem/mL). Diluted solution was used extemporaneously after dilution in 0.9 % NaCI.
Amikacin was supplied by MYLAN LAB (Amiklin®) (50 mg of amikacin/mL). Diluted solution was used extemporaneously after dilution in 0.9 % NaCI.
Results - survival
Results are for presented in Table 1 1 and Figure 29.
Table 1 1 : Effect of antibacterial agent therapy on survival
All animals of the control group died within 48 hours post-infection as expected in this model of acute pneumonia.
The mice administered with compound (I) at 200 mg/kg Q8h for 1 day died also within 48 hours post-infection.
Treatments using meropenem alone or meropenem + compound (I) demonstrated significant efficacy compared to the control group. The combination of compound (I) + meropenem demonstrated increased survival rate (50%) compared to meropenem alone (43%) or compound (I) alone (0%), 72 hours post-infection (Figure 29).
The SAN-94040 strain of A. baumannii has intermediate susceptibility to amikacin, and since amikacin does not penetrate very well into the lungs, it was not unexpected that all animals died within 72 hours post-infection when treated with amikacin alone or with amikacin + compound (I).
Study 2
The aim of this experiment was to assess the bacterial counts in blood, lungs, spleen, liver and kidneys of transiently neutropenic female C3H/HeN mice administered, 3 hours post-inoculation of A. baumannii SAN-94040 via intra-tracheal route, with compound (I) via intra-peritoneal route at 200 mg/kg 3 times daily (every 8 hours) for 1 day alone and in combination with meropenem at 50 mg/kg 3 times daily (every 8 hours) for 1 day or with amikacin at 18 mg/kg 3 times daily (every 8 hours) for 1 day. 90 mice were allocated into 6 groups shown in Table 12.
The SAN-94040 strain of A. baumannii is susceptible to meropenem and has intermediate susceptibility to amikacin.
Table 12: Study 2 design
The test item administration via intra-peritoneal route was initiated 3 hours after inoculation. 90 mice were allocated into 6 groups as follow:
Two vials of 8 mL each containing 93.1 mg of compound (I) and 46.6 mg of PVP 12PF (Kollidon
12PF)/mL were prepared and stored between +02°C and +08°C. Following storage, each vial was homogenized by manual shaking and diluted by 2-fold in 16.17 mg/mL NaCI aqueous solution in order to obtain a 46.5 mg of compound (l)/mL isotonic suspension.
In Groups 2, 5 and 6, mice were administered with 100 μί of the 46.5 mg/mL compound (I) suspension.
Meropenem supplied by ASTRA ZENECA (Meronem®) (50 mg of meropenem/mL). Diluted solution was used extemporaneously after dilution in 0.9 % NaCI.
Amikacin supplied by MYLAN LAB (Amiklin®) (50 mg of amikacin/mL). Diluted solution was used extemporaneously after dilution in 0.9 % NaCI.
Results - bacterial cell counts in the lungs
All results concerning bacterial counts were expressed from Day 0 (inoculation) to 72 hours post-inoculation (Day 3). Bacterial counts on Day 3 were carried out only on surviving mice and results were more objectionable for interpretation. On Day 0, only bacterial count in lung of control mice was performed. Bacterial cell counts were determined as set out in the General Procedures. The results are summarised in Table 13.
Table 13: Results of lung bacterial counts of A. baumannii
CFU / g Lung TO 24h sd* 48 h sd* 72h sd* control 3.33E+06 1.81 E+10 1.58E+W 1.82E + 10 7.91E+09 2.50E+02 i.ooE+oo compound (1) 4.72E +09 4.99E+09 3.75E+05 1.00E+00
amikacin 1.33E+09 2. WE+09 4.41 E +08 6.24E+08
meropenem 3.75E+04 4.90E+04 5.56E +06 7.86E+06 1.OOE+00 i.ooE+oo compound (1) +
6.86E+08 1.19E+09 1.31 E +09 7.95E+08 3.57E+02 i.ooE+oo amikacin
compound (1) +
3.22E +03 2.56E+03 1.18E +09 1-66E+09 5.85E+05 7.61E+04 meropenem
*standard deviation
At 24 h and 48 h after inoculation, control mice had positive lung cultures, reflecting the virulence of the infection model. At 24h after inoculation, administration of a combination of compound (I) with meropenem reduced bacterial counts in lungs compared to control, and the reduction was greater than with administration of compound (I) or meropenem alone. At 24h after inoculation, administration of a combination of compound (I) with amikacin reduced bacterial counts in lungs compared to control, and the reduction was greater than with administration of compound (I) or amikacin alone.
Results - bacterial cell counts in the blood
Bacterial cell counts were determined as set out in the General Procedures. The results are summarised in Table 14.
Table 14: Results of blood bacterial counts of A. baumannii
CFU / ml_ Blood TO 24h sd* 48h sd* 72h sd*
Control - 1 .5 106 2.2 10e 3 106 4 106 0 0 compound (I) - 2.4 10ΰ 4 106 3 10 0 - amikacin - 1 .3 107 1.5 107 1 .6 104 1.9 104 - meropenem - 0 0 0 0 0 0 compound (I) +
amikacin 1 .4 103 2 1(f 7.5 106 1 107
compound (I) +
meropenem 7.3 102 1.3 1(f 0 0 0 0
*standard deviation
At 24h after inoculation, administration of a combination of compound (I) and amikacin reduced bacterial blood counts compared to control, and the reduction was greater than with administration of compound (I) or amikacin alone. At 48h after inoculation, administration of a combination of compound (I) and meropenem reduced the bacterial blood counts compared to control and reduced the bacterial blood count to zero.
Results - bacterial cell counts in the spleen
Bacterial cell counts were determined as set out in the General Procedures. The results are summarised in Table 15.
Table 15: Results of spleen bacterial counts of A baumannii
CFU / g Spleen TO 24h sd* 48h sd* 72h sd*
Control - 2.5 108 4.3 10s 1 .7 108 2.5 10s 0 0 compound (1) - 7.2 108 1.2 10? 2.4 105 0 -
Amikacin - 3.7 108 5.7 10s 6.8 10ΰ 9.5 1(f - meropenem - 2.4 104 1.9 104 1 .25 103 1.7 103 0 0 compound (1) +
amikacin 2.3 106 4 106 2.3 104 2.8 104 0 0 compound (1) +
meropenem 3.7 105 3.7 10s 1 .7 105 1.9 10s 8.3 102 1.2 103
*standard deviation
At 24h and 48h after inoculation, administration of a combination of compound (I) and amikacin reduced bacterial spleen counts compared to control, and the reduction was greater than with administration of compound (I) or amikacin alone. At 24h and 48h after inoculation, administration of a combination of compound (I) and meropenem reduced bacterial spleen counts compared to control and the reduction was greater than with administration of compound (I) alone.
Results - bacterial cell counts in the liver
Bacterial cell counts were determined as set out in the General Procedures.
Table 16: Results of liver bacterial counts of Acinetobacter baumannii
CFU / g Liver TO 24h sd* 48h sd* 72h sd*
Control - 1 .46 108 1.75 10s 1 .12 107 1.6 107 0 0 compound (I) - 1 .05 108 1.8 10s 2.4 105 0 - amikacin - 1 .03 107 1.75 107 1 .8 105 1.4 10s - meropenem - 1 .75 105 2.8 10s 0 0 0 0 compound (I) +
amikacin 1 .3 105 2.11 10s 6.6 104 9.3 104 0 0 compound (I) +
meropenem 1 .1 105 1.20 10s 8.4 103 1.16 104 0 0
*standard deviation
At 24h and 48h after inoculation, administration of a combination of compound (I) and amikacin reduced bacterial liver counts compared to control, and the reduction was greater than with administration of compound (I) or amikacin alone. At 24h and 48h after inoculation, administration of a combination of compound (I) and meropenem reduced bacterial liver counts compared to control and the reduction was greater than with administration of compound (I) alone.
Results - bacterial cell counts in the kidneys
Table 17: Results of kidney bacterial counts of Acinetobacter baumannii
compound (1) - 2.36 108 10s 2.4 105 o - amikacin - 1 .09 107 1.8 io7 6.8 105 9.710s - meropenem - 1 .34 104 toe io4 0 o 0 o compound (1) +
amikacin 1 .28 105 2.210s 1 .35 106 4.910s 0 o compound (1) +
meropenem 4.31 102 4.5 io2 4.7 105 6.710s 0 o
*standard deviation
At 24h after inoculation, administration of a combination of compound (I) and amikacin reduced bacterial kidney counts compared to control, and the reduction was greater than with administration of compound (I) or amikacin alone. At 24h after inoculation, administration of a combination of compound (I) and meropenem reduced bacterial kidney counts compared to control, and the reduction was greater that with administration of compound (I) alone or meropenem alone.
Study 3
The aim of this experiment was to assess the survival rate of transiently neutropenic female C3H/HeN mice administered, 3 hours post-inoculation of A. baumannii RCH-69 via intratracheal route, with a compound (I) via intra-peritoneal route at 200 mg/kg 3 times daily (every 8 hours) for 3 days alone and in combination with meropenem at 50 mg/kg 3 times daily (every 8 hours) for 3 days or with colistin at 125000 Ul/kg 3 times daily (every 8 hours) for 3 days. 85 mice were allocated into 6 groups as follows.
The RCH-69 strain of A. baumannii has low susceptibility to imipenem, is assumed to have a low susceptibility to meropenem and is resistant to amikacin.
Table 18: Study 3 design
The test item administration via intra-peritoneal route was initiated 3 hours after inoculation. 85 mice were allocated into 6 groups as follow:
* number of mice
Six vials of 8 mL each containing 94.2 mg of compound (l)/mL and 47.1 mg of PVP 12PF
(Kollidon 12PF)/mL were prepared and stored between +02°C and +08°C. Following storage, each vial was homogenized by manual shaking and diluted by 2-fold in 13.72 mg/mL NaCI aqueous solution in order to obtain a 47.1 mg of compound (l)/mL isotonic suspension.
In Groups 2, 4 and 5, mice were administered with 100 μί of the 47.1 mg/mL compound (I) suspension.
Results - survival
Results are presented in Table 19 and Figure 30.
Table 19: Effect of antibacterial agent therapy on survival
All animals of the control group died within 48 hours following the inoculation of Acinetobacter baumannii RCH-69 (intermediate to imipenem and susceptible to colistin) as expected in this model of acute pneumonia. The mice administered with compound (I) at 200 mg/kg Q8h for 3 days died within 48 hours post-infection and the mice administered with meropenem at 50 mg/kg Q8h for 3 days died also within 48 hours post-infection as expected as RCH-69 strain has a low susceptibility to carbapenems.
Treatments using a combination of compound (I) and meropenem or a combination of meropenem and colistin exhibited significant efficacy compared to the control group or compound (I) alone or meropenem alone. A combination of compound (I) and meropenem demonstrated increased survival rate (40%) compared to a combination of meropenem and colistin (20%) at 48 hours post-infection (Figure 30).
Conclusion - in vivo studies
In the survival study, combinations of compound (I) with meropenem and compound (I) with amikacin both demonstrated increased survival rates compared to administration of meropenem or amikacin alone, with the compound (I) with meropenem combination being particularly effective. A combination of compound (I) with colistin was shown to exhibit greater efficacy than administration of compound (I) alone.
Bacterial cell count studies indicated that, depending on the organ/system in question, at different time points after administration the combinations of compound (I) with meropenem and compound (I) with amikacin led to a lower bacterial count than administration of any as a monotherapy.
Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps.
Claims
Claims
A method of treating microbial infection comprising administering to a subject in need thereof a therapeutically effective amount of:
(a) 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide; and
(b) an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide for use in treating microbial infection in a subject, in a therapeutic regimen comprising said 4-(4-Ethyl-5-fluoro-2- hydroxyphenoxy)-3-fluorobenzamide in combination with an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
An antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam for use in treating microbial infection in a subject, in a therapeutic regimen comprising said antibacterial agent in combination with 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide.
Use of 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide and an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam in the manufacture of a medicament for use in treating microbial infection.
A method according to claim 1 , 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 2, an antibacterial agent for use according to claim 3, or the use according to claim 4, wherein the antibacterial agent is a carbapenem and is selected from the group consisting of meropenem, imipenem, ertapenem, doripenem, panipenem and biapenem, suitably meropenem and imipenem.
A method according to claim 5, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 5, an antibacterial agent for use according to claim, or the use according to claim 5 wherein the antibacterial agent is meropenem.
A method according to claim 1 , 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 2, an antibacterial agent for use according to claim 3, or the use according to claim 4, wherein the antibacterial agent is an aminoglycoside and is selected from the group consisting of amikacin, gentamicin, tobramycin, arbekacin, kanamycin, neomycin, netilmicin, paromomycin, rhodostreptomycin, streptomycin and apramycin, suitably amikacin, gentamicin and tobramycin.
A method according to claim 7, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 7, an antibacterial agent for use according to claim 7, or the use according to claim 7, wherein the antibacterial agent is amikacin.
9. A method according to claim 1 , 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 2, an antibacterial agent for use according to claim 3, or the use according to claim 4 wherein the antibacterial agent is a polymixin and is selected from the group consisting of colistimethate sodium and colistin sulfate.
10. A method according to claim 9, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 9, an antibacterial agent for use according to claim 9, or the use according to claim 9 wherein the antibacterial agent is colistimethate sodium.
1 1 . A method according to claim 1 , 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 2, an antibacterial agent for use according to claim 3, or the use according to claim 4, wherein the antibacterial agent is a glycylcycline and is tigecycline.
12. A method according to claim 1 , 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 2, an antibacterial agent for use according to claim 3, or the use according to claim 4, wherein the antibacterial agent is rifampicin.
13. A method according to claim 1 , 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 2, an antibacterial agent for use according to claim 3, or the use according to claim 4, wherein the antibacterial agent is sulbactam.
14. A method according to any one of claims 1 to 13, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)- 3-fluorobenzamide for use according to any one of claims 2 to 13, an antibacterial agent for use according to any one of claims 3 to 13, or the use according to any one of claims 4 to 13 wherein the microbial infection is a human or animal infection by Acinetobacter.
15. A method according to claim 14, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 14, an antibacterial agent for use according to claim 14, or the use according to claim 14, wherein the microbial infection is a human or animal infection by Acinetobacter baumannii.
16. A method according to claim 14 or claim 15, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 14 or claim 15, an antibacterial agent for use according to claim 14 or claim 15, or the use according to claim 14 or claim 15, wherein the microbial infection is associated with a disease or disorder selected from the group consisting of a blood stream infection, a urinary tract infection, meningitis, a wound infection (especially in a burns patient) and pneumonia (especially in a patient on mechanical ventilation).
17. A method according to any one of claims 1 to 16, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)- 3-fluorobenzamide for use according to any one of claims 2 to 16, an antibacterial agent for use according to any one of claims 3 to 16 or the use according to any one of claims
4 to 16, wherein said 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide and said antibacterial agent are both administered intravenously.
18. A method according to claim 17, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 17, an antibacterial agent for use according to claim 15, or the use according to claim 17, wherein said 4-(4-ethyl-5-fluoro-2- hydroxyphenoxy)-3-fluorobenzamide and said antibacterial agent are administered simultaneously.
19. A method according to claim 17, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 17, an antibacterial agent for use according to claim 17, or the use according to claim 17 wherein said 4-(4-ethyl-5-fluoro-2- hydroxyphenoxy)-3-fluorobenzamide and said antibacterial agent are administered sequentially.
20. A method according to claim 19, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 19, an antibacterial agent for use according to claim 19, or the use according to claim 19, wherein said 4-(4-ethyl-5-fluoro-2- hydroxyphenoxy)-3-fluorobenzamide is administered prior to said antibacterial agent.
21 . A method according to claim 19, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide for use according to claim 19, an antibacterial agent for use according to claim 19, or the use according to claim 4, wherein said antibacterial agent is administered prior to said 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide.
22. A pharmaceutical composition comprising:
(a) 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide; and
(b) an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
23. A pharmaceutical composition according to claim 22, wherein the antibacterial agent is selected from the group consisting of meropenem, imipenem, amikacin, gentamicin, tobramycin, colistin and tigecycline, rifampicin and sulbactam.
24. A pharmaceutical composition according to claim 22, wherein the antibacterial agent is a carbapenem and is selected from the group consisting of meropenem, imipenem, ertapenem, doripenem, panipenem and biapenem, suitably meropenem and imipenem.
25. A pharmaceutical composition according to claim 24, wherein the antibacterial agent is meropenem.
26. A pharmaceutical composition according to claim 22, wherein the antibacterial agent is an aminoglycoside and is selected from the group consisting of amikacin, gentamicin, tobramycin, arbekacin, kanamycin, neomycin, netilmicin, paromomycin,
rhodostreptomycin, streptomycin and apramycin, suitably amikacin, gentamicin and tobramycin.
27. A pharmaceutical composition according to claim 26, wherein the antibacterial agent is amikacin.
28. A pharmaceutical composition according to claim 22, wherein the antibacterial agent is a polymixin and is selected from the group consisting of colistimethate sodium and colistin sulfate.
29. A pharmaceutical composition according to claim 28, wherein the antibacterial agent is colistimethate sodium.
30. A pharmaceutical composition according to claim 22, wherein the antibacterial agent is a glycylcycline and is tigecycline.
31 . A pharmaceutical composition according to claim 22, wherein the antibacterial agent is rifampicin.
32. A pharmaceutical composition according to claim 22, wherein the antibacterial agent is sulbactam.
33. A kit of parts comprising:
(a) a pharmaceutical composition comprising 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3- fluorobenzamide; and
(b) a pharmaceutical composition comprising an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampicin and sulbactam.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361871590P | 2013-08-29 | 2013-08-29 | |
US61/871,590 | 2013-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015028104A1 true WO2015028104A1 (en) | 2015-03-05 |
Family
ID=49117870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/068528 WO2015028104A1 (en) | 2013-08-29 | 2013-09-06 | Novel drug combination |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015028104A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011026529A1 (en) * | 2009-09-01 | 2011-03-10 | Fab Pharma Sas | Novel antibacterial hydroxyphenyl compound |
-
2013
- 2013-09-06 WO PCT/EP2013/068528 patent/WO2015028104A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011026529A1 (en) * | 2009-09-01 | 2011-03-10 | Fab Pharma Sas | Novel antibacterial hydroxyphenyl compound |
Non-Patent Citations (4)
Title |
---|
C SOULAMA-MOUZE ET AL: "F-2067 52 nd ICAAC Activity of FAB001 in Combination with Antimicrobial Agents Against Acinetobacter baumannii", 52ND INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICAAC); SAN FRANCISCO, CA, USA; SEPTEMBER 09 -12, 2012, 1 January 2012 (2012-01-01) - 12 September 2012 (2012-09-12), XP055110401, Retrieved from the Internet <URL:http://www.ihmainc.com/filebin/Posters/FabPharma/F-2067.pdf> [retrieved on 20140327] * |
G. N. FORREST ET AL: "Rifampin Combination Therapy for Nonmycobacterial Infections", CLINICAL MICROBIOLOGY REVIEWS, vol. 23, no. 1, 1 January 2010 (2010-01-01), pages 14 - 34, XP055110471, ISSN: 0893-8512, DOI: 10.1128/CMR.00034-09 * |
JOEL FISHBAIN ET AL: "Treatment of Acinetobacter Infections", CLINICAL INFECTIOUS DISEASES, vol. 51, no. 1, 1 July 2010 (2010-07-01), pages 79 - 84, XP055110472, ISSN: 1058-4838, DOI: 10.1086/653120 * |
S. ESCAICH ET AL: "The MUT056399 Inhibitor of FabI Is a New Antistaphylococcal Compound", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 55, no. 10, 1 October 2011 (2011-10-01), pages 4692 - 4697, XP055110434, ISSN: 0066-4804, DOI: 10.1128/AAC.01248-10 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008540507A (en) | Pharmaceutical composition comprising an antibacterial agent and an active ingredient selected from carveol, thymol, eugenol, borneol and carvacrol | |
US10463044B2 (en) | Molecules that inhibit efflux pumps in multi-drug resistant bacteria and uses thereof | |
CN102724983A (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
RU2593363C2 (en) | Compositions containing antibacterial agent and tazobactam | |
ES2588984T3 (en) | New antibacterial hydroxyphenyl compound | |
DK2734203T3 (en) | A pharmaceutical composition for the treatment of a respiratory disease | |
JP6886996B2 (en) | Pharmaceutical composition containing an antibacterial agent | |
JP6525999B2 (en) | Antibacterial composition | |
US20150065416A1 (en) | Novel drug combination | |
Hamada et al. | Clinical efficacy of arbekacin for Gram-negative bacteria | |
WO2015028104A1 (en) | Novel drug combination | |
EP3060208B1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
AU2014338612A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
WO2015125031A1 (en) | Pharmaceutical combinations comprising antibacterial agents | |
WO2015063653A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
EP3116545A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
Ramirez et al. | Guanidinylated Amphiphilic Tobramycin Derivatives Synergize with β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa | |
WO2015159167A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
WO2015150926A1 (en) | Pharmaceutical compositions comprising cefepime or sulbactam | |
CN114989165A (en) | Compound or composition for resisting retention bacteria and biofilm bacteria and application thereof | |
ES2804500T3 (en) | Pharmaceutical compositions comprising antibacterial agents | |
JP2015105267A (en) | COMBINED ANTI-METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS AGENT, AND ANTIBACTERIAL ACTIVITY ENHANCER OF β LACTAM ANTIBIOTIC | |
WO2018193368A1 (en) | Antibacterial compositions | |
Morosini et al. | P1687 Marked tigecycline and colistin synergistic bactericidal effect against a nosocomial epidemic carbapenemase (VIM-1) producing Klebsiella pneumoniae clone | |
Rudilla Mateo et al. | Synergistic antipseudomonal effects of synthetic peptide AMP38 and carbapenems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13758899 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13758899 Country of ref document: EP Kind code of ref document: A1 |